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 Summary - Zusammenfassung 
 
Die Erforschung der genetischen Grundlage von Volkskrankheiten wie 
Bluthochdruck und damit verbundene Endorganschäden ist eine der 
Herausforderungen unserer Zeit. Neben Umweltfaktoren ist die Entstehung der 
linksventrikulären (LV) Hypertrophie (LVH) als ein typischer hypertensiver 
Endorganschaden bedingt durch eine genetische Prädisposition. Die Entdeckung 
solcher Suszeptibilitätsfaktoren ist schwierig auf Grund des multifaktoriellen und 
komplexen Charakters der Erkrankung und erfordert eine geeignete 
Herangehensweise zur Analyse des genetisch determinierten Risikos. Um diesen 
Anforderungen gerecht zu werden wurde eine genomweite Assoziationsstudie als 
Fall-Kontroll-Studie in einem repräsentativen Patientenkollektiv mit Bluthochdruck 
und LVH durchgeführt. In einem zweiten Schritt wurde der Einfluss der 
resultierenden Nukleotidvarianten auf die LV Masse getestet. Die nun vorliegenden 
Kandidaten-Polymorphismen konnten nicht in einer Erweiterung des Ausgangs-
kollektivs oder in zur Verfügung stehenden unabhängigen Patientenproben 
repliziert werden. Auf Grund dessen wurden in einem weiteren Schritt zur 
Verfügung stehende genetische Daten eines LVH Modells aus der Ratte mit Hilfe 
vergleichender Genomik in die Analyse integriert. Es konnten zwei Polymorphismen 
identifiziert werden die eine Assoziation mit bluthochdruckbedingter LVH im 
Menschen zeigen und im Rattengenom innerhalb einer Kopplungsregion für eine 
erhöhte linksventrikuläre Masse liegen. Die beiden Varianten ließen sich robust 
replizieren, sowohl in den erweiterten Proben der Ausgangskohorte als auch in 
unabhängigen Patientenproben. Auch wurde ein weiterer Polymorphismus in dem 
betroffenen Gen (PACS1) gefunden der sich im Kopplungsungleichgewicht zu den 
beiden oben beschriebenen Varianten befindet. PACS1, ein Membranprotein das in 
der Lokalisation des trans-Golgi-Netzwerkes eine Rolle spielt ist somit ein neues 
Kandidatengen für die Entstehung einer LVH als hypertensiver Endorganschaden 
und steht damit weiteren funktionellen Analysen zur Verfügung. 
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1. Introduction 
 
1.1. Genetic dissection of complex traits 
 
Most of the observed phenotypes in all organisms, including behavior or the 
susceptibility to common diseases are genetically complex traits, which are 
controlled by multiple genes. Monogenic or Mendelian traits are complementary to 
complex traits and, as far as the influence of the genetic background on the 
phenotype is concerned, most Mendelian traits presumably possess a multifactorial 
component. In addition, both complex and single-gene traits are affected by 
environmental factors also contributing to the examined phenotypes (Glazier AM 
2002). 
Common diseases such as arterial hypertension, diabetes, age-related macular 
degeneration or heart disease are classical complex traits of increasing public and 
scientific importance due to socioeconomic factors such as rising costs in the public 
health sector. These factors will become even more important since most common 
complex diseases are typical attributes of an aging society. However, the dissection 
of complex traits is a demanding challenge due to incomplete penetrance as well as 
phenotypic and genetic heterogeneity. Several well-established approaches have 
been applied to dissect genetic complex traits including family-based linkage 
analysis and population-based association studies (Lander E and Schork NJ 1994). 
Furthermore, the availability of a set of human genomes has rapidly increased the 
knowledge of human genetic variation, providing a powerful tool to dissect complex 
traits (Frazer KA 2009).  
 
 
 
Introduction 
 
2 
 
1.1.1. The variability and structure of the human genome 
 
Considering the architecture of the human genome is an important step in 
understanding human diversity, which in turn may result in different disease 
susceptibilities. The availability of complete genome sequences rapidly increased 
the knowledge of several forms of human genetic variation, their evolutionary 
history and the correlation between them. Common human genetic variations or 
synonymous polymorphisms with a minor allele frequency of one percent in a 
distinct population can be divided into two different classes: single variations like 
single nucleotide polymorphisms (SNPs) or structural variations like copy number 
variations (CNVs). The human genome contains at least nine to ten million common 
SNPs, hence being the most prevalent variant (Frazer KA 2009). 
Fortunately, it is not necessary to genotype all known SNPs to determine the 
disease influencing polymorphisms due to the block structure of the human 
genome. Genetic variants that are located close to each other tend to be inherited 
together. The association between alleles at linked loci is called linkage 
disequilibrium (LD). LD is structured in haplotype blocks, a particular combination of 
alleles along a chromosome. Haplotypes in the human genome are a result of 
recombination or mutation and the haplotype distribution is influenced by 
population specific factors such as genetic drift, natural selection or the number of 
population founding individuals (Collins A 2009). Therefore, the strength of allelic 
association and the occurrence of a particular haplotype differ between distinct 
populations. Utilizing this phenomenon, the International HapMap Consortium 
discovered haplotype blocks in four representative populations by genotyping 
about 3.1 million SNPs in phase I and II resulting in a SNP density of approximately 
one SNP per kilo base pairs. Overall, 30 trios of northern and western European 
ancestry living in Utah from the Centre d´Etude du Polymorphisme Humain (CEPH) 
collection were assayed called CEU samples (The International HapMap Consortium 
2005; The International HapMap Consortium 2007). The resulting haplotype 
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information can be used to select representative tagging SNPs in order to identify 
genetic variation within haplotype blocks without the necessity to genotype every 
single SNP within this block. The approach provides an important basis for genome-
wide genetic analysis. 
 
 
1.1.2. Family-based Linkage Analyses 
 
As mentioned above, the prevalence of common complex disease results from 
interactions between numerous environmental factors and genetic variation of 
many genes. The identification of the alleles affecting disease risk will help to better 
understand disease etiology. Genome-wide linkage analysis using polymorphic 
markers like microsatellite markers or SNPs spread across the genome is one of the 
most traditional method mapping disease genes (Hirschhorn JN and Daly MJ 2005). 
The basic for linkage analysis was established early on fruit flies. It is the simplest 
form of genetic mapping measuring correlated segregation of Mendelian inherited 
markers for a trait (disease) of interest in families. Given meiotic recombination, 
cosegregating or linked markers are supposed to be located in close proximity to a 
disease influencing gene (Altshuler D 2008). In this way, disease associated genomic 
regions or quantitative trait loci (QTL) for a continuous phenotype are identified 
that are more likely to harbor a causal genetic variant contributing to the trait. Due 
to relatively broad (because of less marker resolution and limited number of meiotic 
breaks) regions the linkage approach requires further investigation such as 
positional cloning or candidate gene approaches. 
While linkage analysis has been proven to be successful in mapping genes 
underlying mono- or oligogenic diseases like Huntington disease (Gusella JF 1983) 
the approach is limited in detecting genes underlying multifactorial complex traits. 
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Despite the identification of linkage regions for disorders like type I diabetes 
(Nisticò L 1996) a lot of human linkage studies in common disease were 
unsuccessful due to several factors including low total heritability, insufficient 
phenotyped families and insufficient power to detect common genetic variants with 
modest effects on disease. Another limitation of linkage mapping in humans is the 
recruitment of a sufficient number of affected families (Almasy L 2009). The use of 
an experimental population of animal models e.g. inbred mouse or rat strains 
counters these limitations due to a large number of family samples and larger 
pedigrees. Therefore linkage mapping in the animal model provides a more 
promising approach in dissecting the nature of common complex diseases.  
 
 
1.1.3. Population-based Association Analyses 
 
Another widely used method identifying genes underlying complex diseases is to 
compare allele or genotypes frequencies of a given variant, mainly SNPs between 
two groups. If a particular genetic variant is observed more often than expected by 
chance among these two groups the variant is called associated with the disease or 
trait of interest. In this case the variant serves as a marker and not as a mandatory 
causal relationship with the disease or trait. Most prevalent, the correlation 
between genetic variants and trait differences is assessed in affected case and 
unaffected comparison control samples on a population scale. These case control 
studies are relatively straightforward due to rapid and sufficient assembly of 
samples. Until now, only candidate gene association studies were performed in 
order to dissect common variants within genes of previously identified linkage 
regions or putative diseased pathways. However, association studies based on one 
or few candidate genes examine only a small fraction of the universe of sequence 
variation in each patient, disregarding the multifactorial nature of complex traits. 
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Moreover, the hypothesis driven approach leads to potential bias in selecting 
candidate genes (Hirschhorn JN and Daly MJ 2005). 
In the recent past, the completion of the human genome project and the progress 
in the International HapMap Project as well as the development of cost-efficient 
high-throughput SNP genotyping platforms assaying hundreds of thousands of SNPs 
simultaneously have set the stage for genome-wide association studies (GWAS). 
GWAS are an important step beyond candidate gene studies because they allow for 
SNP marker queries of the entire genome at levels of high resolution unaffected by 
prior hypotheses. The expanding knowledge of the correlation among SNPs 
generated by the International HapMap Project provides the basis of performing 
genome-wide studies (Pearson TA 2008). GWAS are based on the common disease / 
common variant hypotheses suggesting that a distinct number of variants with 
allele frequencies of more than 1 % to 5 % in the observed population contribute to 
the more common forms of human diseases. These common disease variants 
targeted by GWAS have modest and variable phenotypic effects influenced by 
complex genetics and environmental factors (Collins A 2009; Manolio AT 2009). The 
number of GWAS is exponentially growing addressing several disease categories 
including metabolic, autoimmune, neurodegenerative disease and cancer. 
Numerous, approximately 300 novel genetic loci underlying disease susceptibility 
have been discovered for over 80 phenotypes e.g. HLA-DQAI or HBB in Crohn´s 
disease or IL23R in Psoriasis (Frazer KA 2009; Johnsons AD and O´Donell CJ 2009). 
Despite the recent success of GWAS which use a case control approach, there are 
disadvantages regarding the recruitment of representative affected and unaffected 
samples and possible population stratification due to differences in background 
population. Because of these reasons and due to insufficient sample size or random 
errors associated SNP markers found in GWAS often exhibit a lack of reproducibility 
(Pearson TA 2008). 
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1.1.4. The Use of Comparative Genomics 
 
As mentioned before, several strategies exist to dissect a complex trait. All of these 
approaches exhibit assets and drawbacks regarding their efficiency, effectiveness 
and practicability. Hence, comparative genomics is often a valuable tool to bridge 
between data available from human and animal model studies. 
A considerable part of the human genome consists of conserved sequence regions 
and homologous DNA sections exhibiting sequence similarities to other species 
(orthologs) or within the same organism (paralogs). It is believed that common 
features of different organisms are often encoded by homologous DNA sequences. 
Comparing the genome sequences of different species such as human and rodents 
using sequence alignments algorithms is the major principle of comparative 
genomics. Especially for rodents, extensive collections of physiological and genetic 
data are available surveyed in numerous mouse and rat strains. In particular, the rat 
serves as an excellent model organism for common diseases like hypertension, 
providing a rich source for comparative genomic approaches. Furthermore, the 
overlapping examination of rodent orthologs and genes associated with human 
disease were enabled due to the availability of not only the human but also the 
mouse and rat genome sequences and accessible whole-genome aligned genomes 
(Hardison RC 2003). 
Several promising comparative genomic studies were published in the recent past 
addressing the problem of multifactorial human disorders using available animal 
model data. In 2000 Stoll et. al. published a comparative genomic map targeting 
human hypertension loci based on QTL data from several experimental rat crosses 
in order to select new regions for genetic and functional studies (Stoll M 2000). 
Using a similar comparative genetics approach among mouse and human, known 
human atherosclerosis QTLs could be mapped to homologous QTLs in mice, 
identifying novel candidate genes for atherosclerosis (Wang X 2005).  
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1.2.  Arterial Hypertension and hypertensive end organ damage 
 
According to the current guidelines of the world health organization, arterial 
hypertension is defined as blood pressure values exceeding 140 mmHg for systolic 
blood pressure and 90 mmHg for diastolic blood pressure. Approximately 15 % to 
20 % of the western population suffers from this serious disease (Classen M 2004). 
The arterial hypertension prevalence is projected at one billion cases worldwide 
(Kearney PM 2005). Above 90 % to 95 % of adult hypertension cases are essential or 
primary hypertension which are defined as a hypertension without apparent 
reasons like kidney damage (Carretero OA 2000). As a consequence of 
cardiovascular circulation system stress under continuous high blood pressure 
conditions, end organ damage develops as a hypertensive complication. These 
complications can affect various organs including the brain (e.g. cerebrovascular 
accident), the eye (e.g. hypertensive retinopathy), the kidney (e.g. hypertensive 
nephropathy) or the heart. In the following section, the role of left ventricular 
hypertrophy as typical cardiac end organ damage is discussed. 
 
1.2.1. Left ventricular hypertrophy 
 
The pathological enlargement of the myocardial wall of the left ventricle (LV) with 
or without LV chamber enlargement is called Left Ventricular Hypertrophy (LVH). 
Epidemiological studies identified LVH as an important and independent risk factor 
for several diseases like stroke, myocardial infarction, heart failure and 
cardiovascular death in high-risk patients and the general population (Baessler A 
2006; SMART Study Group 2007). LVH is a common complex disease occurring in   
16 % of white men and 21 % of white women and 33 % to 34 % of African 
Americans. The prevalence in hypertensives varies between 22 % and 60 % (Arnett 
DK 2004; Sharma P 2006). 
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In the past, the LV enlargement was merely understood as an adaptive hypertrophy 
due to increased biomechanical stress like high blood pressure. Besides 
hypertension, several additional risk factors for developing LVH like age, diabetes or 
obesity are known (Arnett DK 2004). Recent studies have shown, that the LV mass 
increase is indeed a compensatory process but the LVH progress and magnitude 
varies despite equal blood pressure levels across individuals and well-comparable 
environmental factors (Baessler A 2006). These findings suggest a heritable 
component in the development of LVH. Furthermore, a normal distribution of LV 
mass in the population was observed, providing evidence that the phenotype is a 
complex quantitative trait influenced by multiple genes (Arnett DK 2009).  
Up to date, mainly candidate gene approaches were applied to dissect the genetic 
background of LVH in human. Several polymorphisms in a number of candidate 
genes in distinct pathways have been identified but not consistently replicated e.g. 
the angiotensin-converting enzyme, the guanine nucleotide-binding protein gene, 
the Ghrelin receptor gene region or the transforming growth factor β1 (Semplicini A 
2001; Baessler A 2006; Xu HY 2009). In the recent past a first pilot case control 
genome-wide association study for LV mass in Caucasians, the HyperGen 
(Hypertension Genetic Epidemiology Network) Study was performed. 11 valid SNPs 
were identified and a intragenic SNP within KCNBI (rs756529) was suggested as a 
valid candidate gene for LVH development (Arnett DK 2009). In addition, a genome-
wide linkage scan for LV mass and function in Caucasian and African-American 
participants of the HyperGen Study population identified a region on chromosome 7 
linked to LV wall thickness in Whites and several LOD peaks in both ethnic groups 
giving evidence for putative genes involved in LVH (Arnett DK 2009; Tang W 2009). 
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1.3. Aim of the study 
 
Finding appropriate preventive and therapeutic methods for common diseases 
including arterial hypertension or the susceptibility for subsequent hypertension 
end organ damages remains a difficult task. It requires the dissection of the 
underlying genetic mechanism and the associated molecular pathways. In this 
study, the relatively unexplored genetic basis for left ventricular hypertrophy (LVH) 
as a prevalent hypertensive end organ damage was studied in order to characterize 
genetic susceptibility loci that determine LV mass and the resulting and LV 
dysfunction. 
LVH as a typical common complex disease requires appropriate methods to 
investigate the underlying genetic basis. Previously reported approaches 
unfortunately do not accommodate for the complex nature of LVH pathogenesis 
and progression. For this reason a genome-wide association study approach was 
chosen to shed light on the disease influencing variants in a representative, well 
phenotyped German population with arterial hypertension and heart disease. 
Subsequently, integration of available linkage data from a rat model combined with 
a comparative genomics approach was used to:  
1) dissect the global mechanism of developing LVH under high blood pressure 
conditions and  
2) to provide a proof-of-concept for the analysis of complex traits. 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Consumables and Kits 
The following consumables and Kits were used: 
100x TE-solution and sodium hypochlorite solution (Sigma-Aldrich Chemie GmbH, 
Steinheim, Ger); TaqMan® SNP Genotyping Assay, TaqMan® Genotyping Master 
Mix, 384-Well reaction plate, MicroAmp® optical adhesive film (Applied Biosystems 
Inc., Foster City, USA); Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen GmbH, 
Karlsruhe, Ger) 
 
2.1.2. Instrumentation 
Tecan Genesis RSP 100 and GENios plate reader (Tecan Deutschland GmbH, 
Crailsheim, Ger); pipettes (Eppendorf AG, Hamburg, Ger); 7900HT Fast Real-Time 
PCR System (Applied Biosystems Inc., Foster City, USA) 
 
2.1.3. Software and internet resources 
BioMart Project (http://www.biomart.org/) 
Ensembl Genome Browser (http://www.ensembl.org/) 
HaploView (http://www.broadinstitute.org/haploview) 
International HapMap Project (http://www.hapmap.org/) 
Microsoft® Office 2007 (Access and Excel) 
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NCBI National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/) 
NetAffyx™ Analysis Center (http://www.affymetrix.com/analysis/index.affx) 
PLINK toolset v1.06 (http://pngu.mgh.harvard.edu/purcell/PLINK/) 
Rat Genome Database (http://rgd.mcw.edu/) 
SISA (
STATA 9.0 (StataCorp LP, Texas, USA) 
Simple Interactive Statistical Analysis, 
http://www.quantitativeskills.com/sisa/) 
SDS 2.3 (Applied Biosystems Inc, Foster City, USA) 
 
 
2.2. Methods 
 
2.2.1. Genome-wide association study design 
The described genome-wide association study (GWAS) resulted from the National 
Genome Research Network (NGFN), a cooperating network of several clinical 
centers and researchers. The entire sample recruitment and collection took place 
within this network. After sample processing for genome-wide genotyping, the 
resulting data was made available for the statistical analysis performed in this 
thesis. The applied statistical methods (chapter 2.2.2) were implemented in two 
software packages: STATA and the open-source PLINK toolset (Purcell S 2007). 
Replication of candidate single nucleotide polymorphisms (SNPs) was performed 
using TaqMan® SNP genotyping and the LIFA facility for high through-put 
genotyping. 
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2.2.1.1. Sample recruitment and characterization 
For the GWAS, two patients groups were recruited within the NGFN network: a 
group of screening samples consisting of affected patients (cases) and healthy 
controls for genome-wide SNP genotyping using array technology (see 2.2.1.3) and 
a group of replications samples, consisting of cases and controls for candidate SNP 
replication. 
Screening cases and replication cases I (see Table 2.1) were selected within a survey 
of patients with arterial hypertension in cardiological rehabilitation hospitals, the 
ESTher (Endorganschäden, Therapie und Verlauf) Register (for further information 
see http://www.esther-register.de/). The ESTher cohort was recruited in about 30 
German rehabilitation hospitals, a total of 1,400 patients were collected over a 
period of six month. Inclusion criteria for the ESTher cohort were known or new 
diagnosed arterial hypertension and a rehabilitation program due to cardiovascular 
disease. 
Arterial hypertension was defined as follows: 
• Blood pressure after a 5 min rest period greater than 140 / 90 mmHg 
(systolic / diastolic) 
• Mean blood pressure (over 24 h) greater than 130 / 80 mmHg 
• Exceeding one of the following blood pressure values during exercise 
electrocardiogram (ECG): 
 
Age 
Blood pressure [mmHg] 
(75 watt) 
Blood pressure [mmHg] 
(100 watt) 
20 -50 185 / 100 200 / 100 
51 – 60 195 / 105 210 / 105 
> 60 205 / 110 220 / 110 
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Left ventricular mass (LVM) was determined using  
 
 
 
(IVSd = end-diastolic interventricular septum thickness, PWd = left ventricular 
posterior wall diameter in diastole, LVEDD = left ventricular enddiastolic diameter, 
all parameters were determined using echocardiography). The normalization of 
LVM for height to the allometric power of 2.7 was used to define left ventricular 
hypertrophy (LVH). Partition values for LVH were 50 (male) or 47 (female) g/m2.7
Healthy controls for screening and replication were available within the NGFN 
network: PopGen controls were recruited in the region of Kiel and were included in 
the PopGen database (Krawczak M 2006). Replication of candidate SNPs was 
performed using KORA-gen F3 controls based on the KORA platform (Wichmann HE 
2005). For detailed information see http://epi.gsf.de/kora-
gen/seiten/kora500k_e.php. All participating patients and control samples were 
Caucasian. In Table 2.1, detailed information of population composition, size and 
available phenotype data is given. 
 (de 
Simone G 2005). Replication samples (cases II) were recruited from the Department 
of Cardiology, Angiology and Pulmology at the Heidelberg University Hospital by the 
group of Dr. med. Norbert Frey. All cases II exhibit an arterial hypertension 
(definition see above) and a striking increase in size of the left ventricle during 
echocardiography. LVH status was determined as described. 
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Table 2.1:  Overall, 3938 DNA samples were included in the replication study. Due to the 
case-control design of the study, screening and replication samples were divided into case 
and control samples. For each group sex ratio, age (with standard deviation, SD), left 
ventricular mass (LVM), left ventricular hypertrophy (LVH), arterial hypertension (a.h.) 
status, 24 h mean systolic blood pressure (s. BP) in mmHg, cardiac heart disease (CHD), 
body mass index (BMI), waist circumference (waist circ.) and diabetes status (Diabetes 
mellitus type I or II) are given (missing data is indicated by “/”). 
Cases and healthy controls of the whole GWAS (n = 3938) 
Characteristics 
Screening samples (n = 969) Replication samples (n = 2969) 
Cases  
(n = 492) 
Controls            
(n = 476) 
Cases I  
(n = 855) 
Cases II       
(n = 470) 
Controls             
(n = 1644) 
sex 
(female/male) 
92 / 400 223 / 253 297 / 501 222 / 248 831 / 813 
female [%] 18.69 46.85 37.22 47.47 50.55 
age (SD) 
[years] 
57.65 ± 10.12 39.59 ± 11.17 54.60 ± 19.18 68.03 ± 9.62 62.52 ± 10.09 
LVM (SD) [g] 
211.48 ± 
74.23 
/ 
257.51 ± 
112.64 
236.62 ± 
45.22 
/ 
LVH % 41.38 / 54.89 87.20 / 
arterial 
hypertension 
all no all all 
770 a.h.         
867 no a.h. 
24h mean s. 
BP [mm Hg] 
124.41 ± 
14.48 
/ 
124.88 ± 
14.64 
/ / 
CHD [%] 84.79 / 77.82 no / 
BMI (SD) 28.87 ± 4.80 / 26.56 ± 10.35 29.37 ± 6.35 27.95 ± 5.16 
waist circ. (SD) 
[cm] 
101.17 ± 
11.70 
/ 
102.21 ± 
12.01 
/ / 
Diabetes (type 
I+II) [%] 
26.42 / 28.07 / / 
 
 
2.2.1.2. DNA preparation 
Blood lymphocytes DNA from cases and controls was isolated in the recruiting 
clinical center using standard techniques (QIAGEN). Quant-iT™ PicoGreen® dsDNA 
Assay Kit was used to quantify the isolated DNA. The Quant-iT™ PicoGreen® dsDNA 
reagent is a Hoechst 33258-based assay for sensitive fluorescent nucleic acid 
staining. The samples were suited at 480 nm and the fluorescence emission 
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intensity was measured at 520 nm using a spectrofluorometer. The required 
dilution series, fluorescence measurement and adjustment to the aspired DNA 
concentration using 0.1 % TE-solution was carried out by means of Tecan Genesis 
RSP 100 and GENios plate reader. 
 
2.2.1.3. Genome-wide SNP genotyping 
Genome-wide SNP genotyping of screening samples was performed by Affymetrix® 
Research Services Laboratory (Affymetrix Inc., San Francisco, USA) using the 
Affymetrix® Genome-Wide Human SNP Array 5.0. The SNP chip represents 500 568 
SNPs, 440 794 SNPs are available using the current Affymetrix® Genotyping Console 
(BAT 2.0). The participating SNPs content was chosen randomly, exhibiting 65 % 
coverage of a standardized central European population (CEU) of the ENCODE 
regions of the International HapMap Project (Bickeböller H 2007). 
In brief, 500 ng total genomic DNA was digested with Nsp I and Sty I restriction 
enzymes and all resulting fragments were ligated to adaptor sequences due to 
cohesive 4 bp overhangs. The fragments were used as PCR templates, after 
amplification the amplicons were purified using polystyrene beads. The purified 
amplicons were fragmented to <100 bp fragments using DNAse I and 3’ biotinylated 
using a terminale deoxynucleotidyl transferase (see Figure 2.1). The labeled DNA 
was hybridized allele specific to 25-mer oligonucleotide probes located on the 
Genome-Wide Human SNP Array 5.0.  Each of the two alleles of an SNP is 
represented by 10 to 14 oligonucleotides, in summary one probe set. The 
biotinylated targets were stained using streptavidin R-phycoerythrin (Matsuzaki H 
2004). 
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Figure 2.1: The principle of the Affymetrix Genome-Wide Human SNP Assay. 
 
Hybridized, stained and washed arrays were scanned using GeneChip® Operating 
Software (GCOS) generating raw data (.CEL files). Genotype calling was performed 
using the updated version of the “Bayesian Robust Linear Model with Mahalanobis 
distance classifier” algorithm (BRLMM-P) and the genotype calls were extracted as 
text files for further analysis (Rabbee N 2006; Affymetrix 2007). Control samples for 
replication were genotyped using the GeneChip® Human Mapping 500K Array Set, 
an analog technology to the Affymetrix® Genome-Wide Human SNP Array 5.0 
unless a separate Nsp I and Sty I digestion for two arrays. Genotypes have been 
determined using the software BRLMM version 1.4.0 with standard settings 
proposed by Affymetrix®. 
digestion 
ligation to adaptors and amplification 
purification 
fragmentation and labeling 
Nsp I/Sty I Nsp I/Sty I 
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2.2.1.4. TaqMan® SNP genotyping 
Candidate SNPs were validated in replication case samples using TaqMan® 
technology in the form of ready-to-use TaqMan® SNP genotyping assays. Each assay 
contains sequence-specific forward and reverse primer to amplify the polymorphic 
sequence of interest and two TaqMan® minor groove binder (mgb) probes, one 
probe labeled with VIC® dye (detecting allele 1 sequence) and one labeled with 
FAM™ dye (detecting allele 2 sequence). The 5’ exonuclease activity of the used 
TaqMan® Genotyping Master Mix containing DNA polymerase (AmpliTaq Gold) 
degrades the probe that has annealed to the template. In that case, the quencher 
and reporter dye lose their proximity allowing fluorescence of the particular 
reporter dye (see Figure 2.2). 
  
 
 
 
 
 
 
 
Figure 2.2: The principle of TaqMan® SNP genotyping. The determination of a T/G 
polymorphism is shown exemplary.  In this case, the T allele is detected matching the VIC® 
dye labeled probe.  
 
 
forward primer 
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5‘ 
5‘ 
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TaqMan® PCR processing was performed using the 7900HT Fast Real-Time PCR 
System under standard PCR conditions (95 °C /10 min denaturing; 40 cycles: 95 
°C/15 s denaturing, 60 °C/1 min annealing and elongation). 2 ng genomic DNA 
served as PCR template in a final PCR reaction volume of 5 µL. After end-point 
fluorescence measurement, the DNA samples were called (allele discrimination, see 
Figure 2.3) and exported as text files for further analysis using SDS 2.3 software.  
 
 
 
Figure 2.3: Allelic discrimination plot for an exemplary SNP. One of the three possible 
genotypes (homozygous AA or BB and heterozygous AB) is displayed for each sample. 
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2.2.1.5. PLINK data formats 
BRLMM-p and BRLMM text files (genotype call code: 0 = AA, 1 = AB, 2 = BB, -1 = not 
called) and TaqMan® calling exports were recoded for usage in the PLINK toolset 
using Microsoft® Office 2007 Access and Excel respectively. Required allele 
information were available using the Affymetrix annotation file downloaded from 
www.affymetrix.com. SNP information was recoded in two basic PLINK data 
formats: PED and MAP files. For optional use, covariate files were generated 
containing the available phenotype data (see Table 2.2). 
 
Table 2.2: Composition of the three applied PLINK data formats, all created as tab-
separated text files and provided with the corresponding ending like *.ped or *.map. 
PED file family ID not necessary, same as ind. ID 
 individual ID unique identifier for each sample 
 paternal ID not necessary, 0 
 maternal ID not necessary, 0 
 sex 1 = male, 2 = female, -9 = missing data 
 phenotype 1 = unaffected, 2 = affected, -9 = missing 
  genotypes 2 characters per sample: 1, 2, 3, 4 (A, C, G, T)  
MAP file chromosome 1-22, X or Y 
 rs# or SNP identifier Affymetrix® probe set ID (SNP_A-…) 
 genetic distance not necessary, 0 
 base-pair position in bp units 
covariate file family ID see PED file 
 individual ID see PED file 
 covariate binary or contonious, one per column 
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2.2.2. Examination of linkage disequilibrium and haplotype blocks 
 
The dissection of candidate SNP regions took place exploiting the block structure of 
the human genome. 
 
2.2.2.1. Linkage Disequilibrium 
Genotype information of interesting SNP region for a Caucasian population were 
downloaded from the homepage of the International HapMap Project (The 
International HapMap Consortium 2007). Dumped genotype data (HapMap Data 
Rel. 24, Phase II, Nov08, on NCBI36 assembly, dbSNP b126) was analyzed using the 
HaploView software package (Barrett JC 2005). The calculated linkage 
disequilibrium (LD) pattern (see Figure 2.4) of the downloaded region was displayed 
using the standard color scheme. The color coding of the standard scheme is 
displayed in Table 2.3. 
 
Table 2.3: Standard color scheme of the HaploView LD diagram. The normalized 
disequilibrium coefficient D’ (disequilibrium coefficient D normalized for the maximum of 
Lewontin´s LD measure Dmax
 
) and the measure of confidence in the value of D’ (log of the 
odds, LOD) yield in a color coding. 
 
 
 
An example of a resulting LD pattern is given in Figure 2.4.    
 D’ < 1 D’ = 1 
LOD < 2 white blue 
LOD ≥ 2 shades of red bright red 
Materials and Methods 
 
21 
 
 
Figure 2.4: Linkage disequilibrium pattern of an exemplary region in the human genome 
downloaded from the International HapMap Consortium for a Caucasian population and 
displayed in HaploView. 15 polymorphic SNPs are located within this region. D’ and LOD 
was calculated between each pair of SNPs and displayed as colored rhomb. 
 
 
2.2.2.2. Haplotype Estimation and tagging SNP selection 
For haplotype estimation, HaploView uses a two marker estimation-maximization 
(EM) algorithm (Barrett JC 2005). Haplotype blocks were selected manually with the 
aid of the color coding described above. In Figure 2.4, a manually chosen black 
framed block is shown. Figure 2.5 shows the resulting haplotype structure of this 
block.  
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Figure 2.5: Haplotype structure of the haplotype block of 13 SNPs estimated by HaploView 
using the downloaded genotype information of the International HapMap Consortium. The 
block is arranged in four possible haplotypes and the frequencies for each haplotype are 
given. Block dissolving tagging SNPs were identified by HaploView and are labeled using 
arrowheads.  
 
The principle of choosing tagging SNPs is displayed in Figure 2.6. A sufficient 
number of SNPs tags the possible haplotypes in a chromosomal region. 
 
 
Figure 2.6: Four possible chromosomal regions are displayed and the resulting haplotype 
structure assuming linkage disequilibrium. The four haplotypes are tagged by genotyping 
three SNPs, the tagging SNPs (Figure: (The International HapMap Consortium 2003)). 
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2.2.3. Linkage Analysis and QTL mapping 
 
All methods related to animal breeding, and genotyping outlined below took place 
in the group of Prof. Dr. med. Reinhold Kreutz, Institute of Clinical Pharmacology 
and Toxicology, CCM/CBF, Charité Universitätsmedizin Berlin. Statistical and 
bioinformatical analysis was performed as part of this thesis. 
 
2.2.3.1. Parental strains and F2
Normotensive parental inbred strain Fischer (F344) and spontaneously hypertensive 
rat, stroke prone (SHRSP) were obtained from existing colonies at the Charité Berlin, 
Prof. R. Kreutz, and were maintained under normal conditions. A F
-intercrossing 
2-intercross 
population (F344 x SHRSP) was generated and 232 male F2
 
-animals were included 
for linkage analysis. Salt loading was performed in all animals at the age of six weeks 
using a 4 % salt by weight diet for eight weeks. 
2.2.3.2. Rat Phenotyping 
At 15 weeks of age, systolic blood pressures were measured by non invasive tail-
cuff method (McKee PA 1971). The rats were killed under ether anesthesia and the 
body weight and the weight of the left ventricle (including septum) were 
determined. For further analysis, left ventricle weight was normalized for body 
weight. Systolic blood pressure and the left ventricle / body weight (LVBW) 
phenotype were tested following a normal distribution within the F2
 
-population. 
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2.2.3.3. Genotyping of microsatellite markers 
A complete genome scan using approximately 10 centiMorgan (cM) - spaced 
polymorphic microsatellite markers or simple sequence length polymorphisms 
(SSLP) was performed in two steps. First, 46 F2-animals exhibiting extreme 
phenotypes were screened for genomic regions with significant results. Subsequent, 
these regions were genotyped using all 232 available F2
 
-animals. The required DNA 
was isolated using standard methods. The appropriate microsatellite markers were 
selected using the Rat Genome Database (RGD). PCR amplification of the 
microsatellite marker region was performed using 5´-radioactive labeled pairs of 
primer. By means of denaturating polyacrylamide (PAA) gel electrophoresis and 
autoradiography the amplicons were visualized. 
2.2.3.4. Linkage Analysis 
Using MAPMAKER/EXP linkage analysis was performed building up a genetic linkage 
map, QTL were identified by means of parametric linkage analysis using 
MAPMAKER/QTL 3.0b (Lander E 1987). Genetic distances were calculated 
considering recombination frequencies using the Kosambi algorithm. The threshold 
for significant linkage was defined as a LOD score of 4.3, suggestive 2.8 (Lander E 
and Kruglyak L 1995). The LOD score at a particular locus is defined as follows: 
 
 
 
The determination of the 95 % confidence interval (CI) of significant QTL was based 
on the drop of one LOD unit from the peak (Rapp JP 2000). 
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2.2.3.5. Comparative mapping 
Comparative mapping of the 95 % CI of the determined QTL was performed in our 
group using the Rat Genome Browser available on the Rat Genome Database. The 
required genomic positions of the appropriate microsatellite markers were received 
using the Rat Genome Database as well. The mapping approach was based on the 
rat genome assembly v3.4 and the human annotation is from the March 2006 
(hg18) assembly. The UCSC (University of California Santa Cruz, 
http://genome.ucsc.edu/) derived alignment net track shows the best rat/human 
chain for the requested region in the rat genome. The chain track was determined 
using a gap scoring system. 
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2.2.4. Statistics 
 
2.2.4.1. Hardy-Weinberg Equilibrium 
The Hardy-Weinberg law describes the genetic equilibrium within an ideal 
population, an infinite random-mating population with constant proportions of 
homo- and heterozygote alleles by means of an algebraic equation. 
Assuming two alleles A and a at one locus three genotypes are possible: AA, Aa and 
aa (see Table 2.4) for a diploid individual. 
 
Table 2.4: Hardy-Weinberg law for two alleles at one single locus. 
 
 
 
         
The equilibrium frequencies for allele A (p) and a (q) are given by 
 
(p+q)² = p² + 2pq + q². 
 
If the allele frequencies in a population are known they can be tested for 
statistically significant deviation, that is in principle the proportion of observed and 
expected allele frequencies. Using chi-squared testing (see 2.2.4.2) Hardy-Weinberg 
deviation is tested generally, for large-scale studies of SNP data Fisher´s exact 
testing is used. The probability of the appearance of heterozygous samples using 
allele frequencies is given by 
Parental gametic 
frequencies for 
alleles A and a 
p(A) q(a) 
p(A) AA Aa 
q(a) Aa aa 
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where  are the number of observed genotypes AA, Aa and aa and  
the number of A alleles (Emigh TH 1980). Disproportions in Hardy-Weinberg 
equilibrium indicate genotyping problems or population structure or, in case 
samples a possible association between the examined phenotype and the observed 
marker. An efficient implementation of exact test for HWE as used in the PLINK 
software package is described by Wiggington et al. (Wiggington JE 2005). 
 
2.2.4.2. Basic allelic association testing 
The comparison of allele appearance in case and control samples may lead to new 
risk factors for the observed phenotype. In genome-wide association studies, for 
example, the allele status for a multitude of SNP loci is detected in cases and 
controls. Three genotypes at one biallelic (A and a) locus are possible where a,…,f is 
the number of observations: 
 
 AA Aa aa ∑ 
case sample a c e a + c + e 
control sample b d f b + d + f 
∑ a + b c + d e + f n 
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Alternatively, the number of alleles can be noted at each locus in the two analysis 
groups:  
 A a ∑ 
case sample 2a + c 2e + c 2a + 2c + 2e 
control sample 2b + d 2f + d 2b + 2d + 2f 
∑ 2a + 2b + c + d 2e + 2f + c +d 2n 
 
An allelic chi-square (χ2
 
) test as implemented in the PLINK software package with 
one degree of freedom was performed to compare the frequency distribution of the 
two alleles in cases and controls, hence identifying a possible association with the 
observed phenotype. Assuming the underlying null hypothesis of no association 
between the variables in the case and control group the chi-square test is: 
 
 
By comparing the χ2
 
 -value to a chi-square distribution, a p-value was calculated for 
each chi-square statistic. A p-value ≤ 0.05 was consid ered to reject the null 
hypothesis, indicating an association between the SNP and the observed phenotype 
(Bickeböller H 2007).  Missingness testing, implemented in the PLINK toolset as well, 
was performed similarly. 
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2.2.4.3. Logistic and linear regression 
Regression models allow the description of the relation of two or more variables in 
form of an algebraic equation. The equation is fitted at the best to observed data by 
means of parameter estimation. In this case the examined phenotype (qualitative or 
quantitative) is the dependent variable Y, all further genetic and non-genetic 
variables are characterized as independent variables (covariables) Xi
 
, i=1,…,n. 
Linear Regression: 
In the case of quantitative data as the dependent variable (i.e. left ventricular mass 
(LVM)), the relation between the dependent and independent variable (i.e. age) can 
be described by means of a simple linear regression fitting a straight line: 
 
 . 
 
The y-intercept is given by the estimated parameter , the slope of the line by the 
estimated parameter  (also named regression coefficient). The dependent variable 
was checked to be a normal variable using the STATA software; otherwise it was 
transformed through an appropriate method to achieve a normal “Gauss” 
distribution. 
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Logistic Regression: 
Logistic regression was applied to describe the correlation between a binary 
dependent variable (i.e. left ventricular hypertrophy (LVH) affected or unaffected 
samples) and an independent variable:  
 
 . 
 
Examine one dependent variable Y and multiple independent variables Xi
 
, i=1,…,n is 
called multivariate linear (or analog logistic) regression: 
. 
 
Modeling, i.e. the influence of a particular genotype (X1) on LVM (linear regression) 
or LVH (logistic regression) considering the age (X2) and sex (X3) of the patients, the 
age and sex adjusted genotype influence on the dependent variable LVM or LVH is 
reflected in the regression coefficient  of X1 or the odds ratio (OR, = ) 
respectively (Bickeböller H 2007). In this case, using PLINK software package, the 
direction of the regression coefficient or OR represents the effect of the tested 
minor allele. For each calculation a model assuming full dominance or recessiveness 
was specified. For this purpose, the genotype variable was coded in a binary 
fashion:  
dominant model  one or two minor alleles have an effect, 
recessive model  only two minor alleles have an effect. 
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Subsequent, t-statistics or Wald statistics (see 2.2.4.4) was performed to determine 
the significance of the calculated regression coefficient or OR (Purcell S 2007). 
 
2.2.4.4. Student´s t-test of slope 
A t-test, that is a statistical hypothesis test following a Student´s t-distribution if the 
null hypothesis is true, is frequently used to prove if the slope of a regression line 
differs significantly from 0.  
 
The t-value is given by 
 
 
where  is the calculated regression coefficient,  the null hypothesis regression 
coefficient and  the according standard error. By means of the t-value a p-value 
was calculated (Kohler U 2005). 
 
2.2.4.5. Multiple-testing correction 
Testing multiple independent null hypotheses in one sample, i.e. testing multiple 
SNP associations in one set of case and control samples, results in an inflation of 
type I errors (rejects the null hypotheses although it is true). For 20 independent 
statistic test carried out at the significance level α = 5%, the probability β of 
erroneously dropping one of the null hypotheses is given by 
 
. 
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To deal with the problem of multiple testing of large-scale testing in genome-wide 
association studies, correction of p-values was performed using the false discovery 
rate (FDR) method by Benjamini-Hochberg using the PLINK software package 
(Benjamini Y and Hochberg Y 1995). 
 
2.2.4.6. Calculation of combined p-values 
Unweighted combined p-values were calculated using the Fisher method. The 
approach combines p-values from a variety of independent test into one statistic 
having a χ2
 
 distribution using the formula: 
. 
 
The resulting combined p-value can be calculated from a χ² table using 2k degrees 
of freedom where k is the number of the combined tests (Fisher RA 1948) available 
on the homepage of SISA (Simple Interactive Statistical Analysis). 
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3. Results 
 
3.1. A genome-wide association study of left ventricular hypertrophy as a 
hypertensive end organ damage 
 
The first part of this work was the dissection of a complex trait like the hypertensive 
end organ damage left ventricular hypertrophy (LVH) by means of a genome-wide 
association study (GWAS). A case control design was chosen in which allele 
frequencies in cases (ESTher samples) with the phenotype of interest were 
compared to those in a control group (PopGen samples). In a first step, the case and 
control screening samples were genotyped using the Affymetrix® SNP Array 5.0. A 
detailed description of the study samples is given in chapter 2.2.1.1.  
 
3.1.1. Quality control and SNP marker recovery 
 
Quality control of the used screening samples (492 cases, 476 controls) and the 
resulting genotype calls was a fundamental part of the GWAS analysis. Overall,    
440 799 SNP markers were available after Genome-Wide Human SNP Array 5.0 
processing. The data was recoded for use in the PLINK toolset (see 2.1.3) as 
described. Permutation testing was performed resulting in a genomic inflation 
factor (based on median χ2) of 1.1615. Hence, population stratification was 
excluded. A minimum rate of 90 % successfully genotyped SNPs per sample was 
applied resulting in 5378 zeroed markers. In addition, a minor allele frequency 
threshold of 5 % was imposed to avoid genotype errors of rare and difficult to call 
SNPs thus eliminating 96 485 SNPs from the input data set. Furthermore, a       
Hardy-Weinberg Equilibrium (HWE) p-value of at least ≥  0.001 in control samples 
was selected as a cut-off value for the respective SNPs (1895 markers failed). 
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Disproportions in Hardy-Weinberg equilibrium may indicate genotyping problems or 
population stratification. A missingness test (χ2
 
 test) was performed to compare 
genotyping rates between cases and controls. A significant (p-value ≤ 0.05) 
deviation was considered to give evidence of differing sample quality and the 
involved SNPs were excluded from analysis. After data pruning, 310 417 SNPs with 
an average call rate of 99.19 % were available for following association analysis. 
3.1.2. Genetic associations in the screening cohort 
 
In a first step, the analysis was restricted to severe cases of LVH derived from the 
ESTher samples according to the guidelines of de Simone. Following the definition 
for LVH with partition values of   50 g/m2.7 (male) or 47 (female) g/m2.7 
 
(see chapter 
2.2.1.1), 204 LVH affected cases were selected from the pool of 492 genome-wide 
genotyped ESTher samples. A detailed description of sample phenotype 
composition is given in Table 3.1. 476 PopGen samples served as control samples. 
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Table 3.1: Phenotype characteristics of cases (ESTher cohort, n=204) and controls (PopGen, 
n= 476) for the first screening of genetic association using extreme cases. Mean age, left 
ventricular mass (LVM) and 24h mean systolic blood pressure (s. BP) are given with the 
respective standard deviation (SD). Missing data is indicated by “/”. 
 
Cases and controls of the screening step (n = 680) 
Characteristics Cases (n = 204) Controls (n = 476) 
sex (female/male) 42 / 162 223 / 253 
female [%] 20.59 46.85 
age (SD) [years] 60.04 ± 10.52 39.59 ± 11.17 
LVM (SD) [g] 274.10 ± 66.41 / 
arterial hypertension all no 
24h mean s. BP [mm Hg] 125.38 ± 15.92 / 
 
All 204 screening cases exhibit arterial hypertension accompanied by a significant 
LVH as typical hypertensive end organ damage. There were no left ventricular mass 
(LVM) data available for the 476 PopGen control samples and hence no LVH status 
calculable. Blood pressure values were not collected as well but a normotensive 
status of control samples was affirmed by the PopGen database operators within 
the NGFN network. There were considerable differences in age between the case 
and the control group: having approximately equivalent standard deviations the 
mean difference was 20.81 years. The sex of the two analysis groups was yet 
another asymmetry of the underlying screening data. The percentage share of 
women in the affected samples was 20.59 %, in the unaffected control samples 
46.85 %. Both, sex and age varieties between the two groups were considered in 
chapter 3.1.2.2 as far as a confounding of allelic association was concerned. 
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3.1.2.1. Basic allelic association 
The analysis of a standard allelic association testing for LVH was performed using an 
allelic χ2
 
 test to compare the extreme cases of the screening cohort and the 
respective control samples described above. 310 417 SNP markers were available 
for this test after quality control and a p-value was calculated for every SNP 
reflecting the significance of association. Table 3.2 summarizes the distribution of 
the resulting p-values (unadjusted and adjusted for multiple testing, 310 417 tests) 
over different groups of minor allele frequencies.  
Table 3.2: Overview of the p-values calculated by a standard allelic association testing 
between ESTher extreme cases (n = 204) and PopGen controls (n = 476) of the screening 
cohort. The minor allele frequencies (MAF) are given and the counts of SNPs with the 
respective p-values (unadjusted and adjusted for multiple testing (310 417 tests) using false 
discovery rate (FDR)). 
 unadjusted p-value adjusted p-value (FDR) 
MAF SNPs ≤ 5*10-2 ≤ 5*10-4 ≤ 5*10-6 ≤ 5*10-2 ≤ 5*10-4 ≤ 5*10-6 
> 5% - ≤10% 2 723 218 78 164 54 13 
> 10% - ≤20% 5 038 163 29 87 12 / 
> 20% - ≤30% 4 362 59 1 17 / / 
> 30% - ≤40% 3 923 40 / 9 / / 
> 40% - ≤50% 3 645 39 / 4 / / 
∑ (SNPs) 19 691 519 108 281 66 13 
 
 
Most of the significantly associated SNPs were found in the group of markers having 
a minor allele frequency of 5 % to 10 %. By trend, the number of significant SNPs 
decreased with increasing minor allele frequencies. Correction for multiple testing 
to avoid false positive SNP associations reduced the amount of SNPs with high 
significance rapidly. This step was necessary because of 310 417 applied χ2 tests to 
determine allelic association. Due to the small number of case samples in this 
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screening step, only markers having a minor allele frequency of 10 % or higher were 
considered to be reliable. The resulting unadjusted p-values (≤ 0.05) of the allelic 
association test for all markers having a minor allele frequency of > 10 % are 
displayed in Figure 3.1 by means of a Manhattan plot.  
 
Figure 3.1:  Manhattan plot of the significantly associated SNPs (n = 16 968, p-value 
unadjusted ≤ 0.05, minor allele frequency >  10 %) resulting from the first genome-wide 
scan of extreme LVH cases and PopGen control samples. The total base pair position for 
each chromosome (color coded) of each SNP is plotted against the negative decadic 
logarithm (-log) of the allelic association p-value.  
 
A Manhattan plot is a good way to annotate genome-wide significance distribution. 
The disproportion of many markers with relatively low significance (-log (p-value) 
from 1.25 to 3) to some markers having a strong association (-log (p-value) greater 
than 5) is visible. Only 13 SNPs showed a genome-wide association of a p-value less 
than 5 * 10-6 (ranging between a p-value of 2.19 * 10-10 and 1.21 * 10-6) but 
exhibiting minor allele frequencies less than 10 % hence not being displayed in 
Figure 3.1. Overall, 36 SNPs exhibiting a minor allele frequency greater than 10 % 
and an unadjusted p-value less than 1 * 10-5 were selected for a closer examination 
in Table 3.3. 
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Table 3.3 (next page): 36 significantly associated SNP markers (adjusted p-value less than   
6 * 10-3 , unadjusted p-value less than 1 * 10-5) resulting from the genome-wide scan of LVH 
cases (extreme cases of ESTher samples, n = 204) and control samples (PopGen samples, n 
= 476) sorted by p-value. Each SNP is characterized by a unique identifier, the probe set ID 
resulting from the design on the SNP Array 5.0. The absolute position of each SNP (bp) is 
given and the respective chromosome. χ2, p-value (unadjusted and adjusted using false 
discovery rate (FDR)) and the estimated odds ratio (OR) for the minor allele arose from the 
allelic association test with one degree of freedom. The minor (A1) and major (A2) allele of 
the respective SNP is given using a numeric code (1 = A, 2 = C, 3 = G, 4 = T). Genotype 
counts for the two alleles in the control sample group are shown for the possible two 
homozygous and one heterozygous allele combinations (A1A1/A1A2/A2A2). In addition, the 
overall determined minor allele frequency (MAF) is assigned. 
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probe set ID chromsome bp χ² p-value p-value (FDR) MAF A1 A2 OR genotype (controls) 
SNP_A-2153126 3 106747807 33.9 5.79E-09 1.53E-05 0.1752 3 1 2.372 11/102/344 
SNP_A-2186482 6 97224557 33.73 6.33E-09 1.61E-05 0.1075 3 1 2.724 1/70/405 
SNP_A-2065547 4 60243814 30.7 3.01E-08 6.03E-05 0.1401 3 2 2.381 10/81/385 
SNP_A-2268977 3 163972160 30.62 3.14E-08 6.22E-05 0.1069 1 3 2.611 1/71/404 
SNP_A-1849414 7 88165999 30.08 4.14E-08 7.71E-05 0.1127 3 2 2.539 2/74/400 
SNP_A-2063755 3 175492037 29.54 5.48E-08 9.53E-05 0.1243 2 3 2.432 4/80/392 
SNP_A-1950636 10 57665797 28.73 8.32E-08 1.29E-04 0.1237 1 3 2.409 3/82/391 
SNP_A-1834522 2 188017098 28.74 9.50E-08 1.43E-04 0.1046 3 2 2.546 2/68/406 
SNP_A-2057907 13 88080858 26.83 2.22E-07 2.86E-04 0.1237 3 4 2.343 8/73/395 
SNP_A-2001186 10 57666414 25.98 3.44E-07 4.16E-04 0.1221 4 2 2.321 3/82/391 
SNP_A-2274638 10 52984415 25.93 3.54E-07 4.25E-04 0.1391 1 2 2.284 5/87/360 
SNP_A-1889369 2 188016885 25.7 3.98E-07 4.59E-04 0.1019 4 2 2.461 2/67/406 
SNP_A-2064767 12 58459673 25.17 5.26E-07 5.73E-04 0.1156 4 2 2.334 5/73/398 
SNP_A-4252877 10 57665722 23.95 9.86E-07 9.67E-04 0.1195 4 2 2.267 3/81/392 
SNP_A-2157397 7 85169965 23.9 1.01E-06 9.83E-04 0.1541 4 3 2.104 3/111/362 
SNP_A-2294633 5 100111301 23.25 1.42E-06 1.27E-03 0.1064 2 4 2.375 0/72/381 
SNP_A-4218138 12 18258531 22.75 1.85E-06 1.55E-03 0.1059 2 1 2.305 3/70/403 
SNP_A-1935686 1 160576937 22.37 2.25E-06 1.82E-03 0.2673 2 4 0.4966 46/193/229 
SNP_A-2101014 2 52831698 22.13 2.55E-06 2.00E-03 0.1269 1 3 2.166 2/90/382 
SNP_A-2074123 4 132182895 22.09 2.60E-06 2.02E-03 0.1125 1 3 2.235 3/76/397 
SNP_A-1835958 1 67114572 21.65 3.28E-06 2.48E-03 0.1159 1 3 2.243 7/65/375 
SNP_A-4265373 5 160998740 21.45 3.64E-06 2.71E-03 0.1637 4 2 1.997 11/105/360 
SNP_A-2158385 8 78611923 21.32 3.88E-06 2.82E-03 0.1252 3 1 2.143 3/87/384 
SNP_A-4260091 11 14680288 21.11 4.34E-06 3.11E-03 0.1047 4 2 2.251 4/68/404 
SNP_A-2107642 4 138261700 21.05 4.48E-06 3.19E-03 0.1108 3 4 2.21 5/71/399 
SNP_A-1917004 3 2329035 21.02 4.55E-06 3.23E-03 0.1024 2 4 2.262 2/70/404 
SNP_A-2048869 8 122183583 21.01 4.57E-06 3.24E-03 0.1049 4 2 2.26 2/71/396 
SNP_A-2011027 11 51285867 20.86 4.93E-06 3.43E-03 0.1105 3 1 2.202 4/73/399 
SNP_A-1931236 9 90569830 20.87 4.93E-06 3.43E-03 0.1554 4 1 2.003 8/104/364 
SNP_A-2291035 12 39000599 20.85 4.97E-06 3.45E-03 0.1625 2 4 1.983 10/106/359 
SNP_A-2140243 18 38926416 20.8 5.10E-06 3.52E-03 0.1854 3 4 1.933 12/120/336 
SNP_A-1858693 2 50341732 20.61 5.63E-06 3.82E-03 0.1495 3 2 2.014 5/105/366 
SNP_A-4295370 8 19576480 20.06 7.51E-06 4.76E-03 0.3905 1 4 0.5683 87/233/154 
SNP_A-1889406 5 155275310 19.93 8.05E-06 5.03E-03 0.1286 3 1 2.133 10/69/361 
SNP_A-2196855 7 80634017 19.92 8.08E-06 5.04E-03 0.1006 1 3 2.233 2/69/404 
SNP_A-1969214 1 160571784 19.57 9.69E-06 5.84E-03 0.2728 1 3 0.5316 45/203/228 
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In Table 3.3, the 36 most significant SNPs were documented having a minor allele 
frequency greater than 10 %. The emerging SNPs were located on the chromosomes 
1 to 13 and 18. The odds ratio (OR) for each SNP association is given: the OR of 33 
markers was greater than 1 (in the range of 1.933 to 2.724, mean 2.27 ± 0.1847 
standard deviation) identifying the minor allele for these SNPs as risk alleles for 
developing LVH as a hypertensive end organ damage. For three SNPs (SNP_A-
1935686, SNP_A-4295370 and SNP_A-1969214) the OR was smaller than 1 and 
consequently, the minor allele seemed to act as a protective genetic component in 
disease manifestation. Furthermore, the genotype distribution in the control group 
was considered. Three allele combinations were possible, homozygous for the 
minor or major allele and the heterozygous case. 27 out of 36 significantly 
associated SNPs appeared having less than 10 homozygous samples for the 
respective minor allele. These SNPs were considered to have low information 
content and were not qualified for advanced analysis. The remaining nine SNPs 
(SNP_A-1969214, SNP_A-1889406, SNP_A-4295370, SNP_A-2140243, SNP_A-
2291035, SNP_A-4265373, SNP_A-1935686, SNP_A-2153126 and SNP_A-2065547) 
were possible candidate SNPs associated with the development of LVH as 
hypertensive end organ damage and were regarded in detail in the following 
analysis in chapter 3.1.2.3.  
 
3.1.2.2. Age and sex adjustment of the screening cohort  
As shown in Table 3.1, considerable differences in age and sex proportion between 
the case and the control group were present in the screening samples. Using logistic 
regression and subsequently t-statistic to calculate p-values, the influence of the 
detected allelic status and further so called covariates (age and sex) on the 
phenotype (affected and unaffected samples) were tested. In this way, the required 
age and sex corrected SNP associations were calculated. Assuming full dominance 
(or recessiveness) for the minor allele two models were specified and applied on 
the same dataset as the basic allelic association. The dataset consisted of 204 cases 
Results 
 
41 
 
having a clear LVH and 476 control samples. Quality filtering was performed as 
described in chapter 3.1.1 and a set of 310 417 SNPs were available for age and sex 
adjustment. The Manhattan Plots in Figure 3.2 and 3.3 and Table 3.4 and 3.5 show 
the association results. 
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Figure 3.2: Manhattan 
Plot of the age and sex 
corrected genome-wide 
marker association using 
logistic regression, 
adjusted for age and sex 
and assuming full 
dominance of the minor 
allele. The –log (p-value) 
of all significant SNP 
(unadjusted p-value ≤ 
0.05, n = 18 106) are 
plotted against the 
chromosomal position. 
Figure 3.3: Manhattan 
Plot of the age and sex 
corrected genome-wide 
marker association using 
logistic regression, 
adjusted for age and sex 
and assuming full 
recessiveness of the 
minor allele. The –log (p-
value) of all significant 
SNP (unadjusted p-value 
≤ 0.05, n = 15 304) are 
plotted against the 
chromosomal position. 
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Table 3.4: Results of genome-wide association using logistic regression (correction for age and sex), assuming full dominance of the minor allele (A1). 
The localization of the respective SNP markers (identified by the probe set ID) is given by the chromosome and the absolute base pair (bp) position. The 
unadjusted and adjusted (FDR, false discovery rate) p-value resulting from logistic regression and subsequently t-statistic, the minor allele frequency, 
the odds ratio (OR) and the genotype appearance in the control samples are given. All SNPs showing an unadjusted p-value ≤ 1 * 10-5
 
 are listed. 
 
Table 3.5: Results of genome-wide association results using logistic regression, assuming full recessiveness of the minor allele (A1). The given 
characteristics are comparable to those in Table 3.4. The SNP associations are corrected for age and sex. All SNPs showing an unadjusted p-value             
≤ 1 * 10-5
 
 are listed. 
probe set ID chromosome bp p-value p-value (FDR) MAF A1 A2 OR genotype (controls) 
SNP_A-2186482 6 97224557 1.37E-08 7.48E-04 0.1075 3 1 5.768 1/70/405 
SNP_A-2011027 11 51285867 4.21E-08 1.41E-03 0.1105 3 1 5.306 4/73/399 
SNP_A-2064936 11 65741744 1.63E-07 2.95E-03 0.2574 4 2 4.096 24/176/276 
SNP_A-2270325 1 199804108 5.24E-06 9.44E-03 0.2912 3 1 0.3011 43/200/233 
SNP_A-2079405 11 65711257 6.95E-06 1.08E-02 0.2 2 1 3.311 19/137/320 
SNP_A-2086003 2 64251922 7.39E-06 1.12E-02 0.1295 3 1 3.761 9/86/375 
SNP_A-2069616 20 2676570 7.41E-06 1.12E-02 0.1213 2 4 3.894 7/86/382 
probe set ID chromosome bp p-value p-value (FDR) MAF A1 A2 OR genotype (controls) 
SNP_A-2060349 1 198896407 2.82E-06 1.02E-01 0.1632 4 2 33.08 8/118/350 
SNP_A-2262176 10 9662849 7.93E-06 1.81E-01 0.4919 2 4 3.712 105/241/129 
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Figure 3.2 and Figure 3.3 display all significant SNP associations (unadjusted p-value 
≤ 0.05) of the genome-wide scan between the LVH affected samples of the ESTher 
cohort (n = 204) and the PopGen control samples (n = 476) corrected for age and 
sex of the respective samples for chromosome 1 to 22. The sex chromosomes were 
not tested because the regression method uses genotype data in contrast to the 
allelic test. The resulting p-values assuming full dominance of the minor allele are 
displayed in Figure 3.2 by means of a Manhattan plot. 18 106 SNPs showed a p-
value ≤ 0.05 and most of the significant associations lay within a range from 0.05 to 
0.0005 (range of negative logarithm from approximately 1.3 to 3.5). The number of 
associated makers decreased rapidly by increasing significance. Only seven 
associated SNPs with an unadjusted p-value ≤ 1 * 10-5 after age and sex correction 
were detected, shown in Table 3.4. The seven SNPs are located on chromosome 1, 
2, 6, 11 and 20 and after adjustment for multiple testing using false discovery rate, 
all SNPs kept a minimum p-value ≤ of 0.05. Except  for one allele with a protective 
effect on developing a LVH under high blood pressure (minor allele of              
SNP_A-2270325), all of the minor variants increased the risk for the manifestation 
of LVH. For the calculation of the dominant model during logistic regression an 
effect of one or two minor alleles is assumed. Hence, the genotype distribution of 
the homozygous minor allele of the controls was negligible. All SNPs are possible 
candidates and were regarded in detail in the following analysis in chapter 3.1.2.3. 
In Figure 3.3, the Manhattan plot for the recessive model is displayed. As described 
for Figure 3.2, the number of SNP markers decreased with increasing significance 
level of association. In general, fewer SNPs were significantly associated with the 
examined phenotype in the recessive model (n = 15 304) and  p-values were smaller 
than the corrected p-values in the dominant model. Only two markers were 
associated under recessive conditions exhibiting a p-value ≤ 1 * 10-5 (see Table 3.5). 
Both p-values were not significant (threshold ≤ 0.05) after correction for multiple 
testing. The OR were greater than 1, thus the respective minor allele of the two 
SNPs is a risk allele for developing LVH. Assuming full recessiveness (only two minor 
alleles have an effect on the examined phenotype), the genotype distribution of 
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SNP_A-2060349 was not significant because of only having eight homozygous 
samples in the controls samples for the minor allele and the marker was rejected 
for further analysis. 
Two SNPs were associated significantly (unadjusted p-value ≤ 1 * 10-5) both in basic 
allelic association testing (see Table 3.3) and after logistic regression corrected for 
age and sex (dominant model, see Table 3.4): SNP_A-2011027 (chromosome 11) 
and SNP_A-2186482 (chromosome 6). The significance level of SNP_A-2011027 was 
raised due to age and sex correction from p-value 4.93 * 10-6 to 1.374 * 10-8 and the 
respective OR was 5.768 after logistic regression (OR 2.202 after allelic association 
testing). The significance level of SNP_A-2186482 acted reversely, before correction 
for age and sex the p-value was 6.33 * 10-9 and afterwards 4.21 * 10-8
 
. However, the 
OR was increased from 2.724 to 5.306. 
3.1.2.3. Left ventricular mass as a quantitative trait 
Up to date, genetic association screening was based on a case control approach, 
typing affected cases having a distinct LVH under high blood pressure conditions    
(n = 204) against healthy control samples (n = 476). The LVH status was coded 
binary for cases and controls, whereas the dimension of the left ventricle related to 
the body height has to exceed a distinct threshold. Another approach for finding 
SNPs that influence the examined phenotype is to look at the left ventricular mass 
as a continuous, quantitative trait. Linear regression was applied on the 17 selected 
SNPs resulting from chapter 3.1.2.1 and 3.1.2.2 dealing this approach using the 
STATA software package. The genotype data of all 492 screening cases was applied 
though having a distinct LVH by definition because all of the available genome-wide 
genotyped ESTher samples exhibit hypertension in combination with increased left 
ventricular masses. The dependent variable left ventricular mass (LVM, in grams) 
was checked to be a normal variable using the STATA software and was 
transformed to normal distribution using the forth root of the raw data. Linear 
regression and subsequently t-statistics yielding a p-value was calculated for the 17 
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candidate SNPs, assuming full dominance or recessiveness of the minor allele (see 
Table 3.6 and 3.7). The regression coefficient for each association is given indicating 
the effect of the minor allele on the size of the left ventricle. The effect unit is the 
forth root of the LVM in grams as well.  
 
probe set ID regression coeffcient p-value 95 % CI 
SNP_A-2153126 0.0492869 0.12 -0.0129495 0.1115233 
SNP_A-2065547 0.0587992 0.059 -0.0021471 0.1197454 
SNP_A-1935686 -0.0577603 0.059 -0.1177215 0.002201 
SNP_A-4265373 0.0693444 0.022 0.0098342 0.1288546 
SNP_A-2291035 0.0668625 0.028 0.0072932 0.1264318 
SNP_A-2140243 0.0642904 0.028 0.0069798 0.121601 
SNP_A-4295370 -0.0561534 0.057 -0.1139831 0.0016762 
SNP_A-1889406 0.0142838 0.65 -0.0474832 0.0760508 
SNP_A-1969214 -0.045509 0.124 -0.1034696 0.0124517 
SNP_A-2086003 0.0720394 0.034 0.0055242 0.1385546 
SNP_A-2079405 0.0164062 0.586 -0.0426997 0.0755121 
SNP_A-2064936 -0.0054076 0.853 -0.0628499 0.0520348 
SNP_A-2270325 0.0093319 0.751 -0.0483928 0.0670565 
SNP_A-2262176 -0.0388983 0.216 -0.1006153 0.0228186 
SNP_A-2186482 0.1234248 0.000 0.060743 0.1861067 
SNP_A-2011027 0.0584496 0.076 -0.006235 0.1231342 
SNP_A-2069616 0.0570635 0.689 -0.223325 0.337452 
 
Table 3.6: Results of linear regression for 17 SNPs resulting from the case control approach 
using genotype data of 492 genome-wide typed ESTher samples assuming full dominance 
of the minor allele. The regression coefficient (  ) and the respective 95 % 
confidence interval (CI) is given showing the effect direction of the minor allele. The p-value 
is given; a significance threshold of ≤ 0.05 was applied.  Significant p-values are highlighted 
red. 
 
Five of 17 SNPs showed significant (p-value ≤ 0.05) associations to LVM. All of them 
increased the LVM in a range between 0.064 and 0.123. The minor allele of    
SNP_A-2186482 having a p-value of ≤ 0.001 in the dominant model affected the 
LVM most strongly (  = 0.1234248). The remaining markers had moderate effects 
on LVM and the p-values were less significant. The effect of the SNP variants on 
LVM as far as the recessive model is concerned is displayed in Table 3.7. Six 
significant associations (p-value ≤ 0.05) were determined in which two minor alleles 
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of three loci (SNP_A-1935686, SNP_A-4295370 and SNP_A-1969214) lower LVM in a 
range between about – 0.09 to – 0.16. The remaining three SNPs increased the LVM 
(about 0.17) and all in all, the impact of the analyzed SNPs assuming full 
recessiveness on LVM was greater than under dominant conditions. One marker 
showed comparable significant results in both models, SNP_A-4265373. In both 
models, an increasing effect on LVM was detected. Overall, 10 SNPs had a 
significant effect on the LVM and were considered for further analyses. 
 
probe set ID regression coeffcient p-value 95 % CI 
SNP_A-2153126 0.1671072 0.002 0.0622322 0.2719822 
SNP_A-2065547 0.17909 0.04 0.007926 0.3502541 
SNP_A-1935686 -0.1545467 0.01 -0.2718357 -0.0372578 
SNP_A-4265373 0.1798286 0.029 0.0187055 0.3409516 
SNP_A-2291035 0.0865946 0.343 -0.0925197 0.2657089 
SNP_A-2140243 0.0107776 0.901 -0.1588736 0.1804289 
SNP_A-4295370 -0.0910379 0.031 -0.1738216 -0.0082542 
SNP_A-1889406 -0.0590533 0.584 -0.2710481 0.1529415 
SNP_A-1969214 -0.1559418 0.01 -0.2749293 -0.0369542 
SNP_A-2086003 0.0422535 0.62 -0.1251929 0.2096998 
SNP_A-2079405 0.0254872 0.713 -0.1103671 0.1613414 
SNP_A-2064936 0.0178307 0.754 -0.0937827 0.129444 
SNP_A-2270325 -0.0084844 0.881 -0.1199909 0.103022 
SNP_A-2262176 0.0228788 0.506 -0.0446179 0.0903755 
SNP_A-2186482 0.591369 0.066 -0.0390478 1.221786 
SNP_A-2011027 -0.1462865 0.317 -0.4332742 0.1407013 
SNP_A-2069616 -0.0245482 0.458 -0.089553 0.0404566 
 
Table 3.7: Results of linear regression (recessive model) for 17 SNPs resulting from the case 
control approach using genotype data of 492 genome-wide typed ESTher samples. The 
regression coefficient (  ) and the respective 95 % confidence interval (CI) is given 
showing the effect direction of the minor allele. The p-value is given; a significance 
threshold of ≤ 0.05 was applied. Significant p-values are highlighted red. 
 
In the next step, the linear regression findings (10 SNPs) were corrected for 
additional covariates. For the well phenotyped 492 ESTher screening samples (see 
Table 2.1) phenotype data were available having a putative effect on the LVM. The 
age, sex, waist circumference, body mass index, the mean value of blood pressure 
measurement over 24 hours (systolic), diabetes status and the appearance of 
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cardiac heart disease per patient were used as covariates and the linear regression 
(dominant and recessive model) was applied once again on the 10 significant SNPs 
shown in Table 3.6 and 3.7. Five SNPs with a significant effect on LVM were 
determined using the dominant model (see Table 3.8) and showed the same trend 
in regression coefficient expect of SNP_A-1935686. The p-value of this marker was 
0.059 before and 0.017 after covariate correction. SNP_A-2140243 lost the 
significant impact on LVM, the p-value dropped from 0.028 to 0.122.  
 
probe set ID regression coefficient p-value 95 % CI 
SNP_A-2153126 0.0568401 0.06 -0.0023495 0.1160296 
SNP_A-2065547 0.0174572 0.532 -0.0374219 0.0723364 
SNP_A-1935686 -0.0694063 0.017 -0.1262214 -0.0125912 
SNP_A-4265373 0.0613817 0.034 0.0046712 0.1180921 
SNP_A-2291035 0.0718743 0.014 0.0147586 0.1289899 
SNP_A-2140243 0.0436474 0.122 -0.011667 0.0989618 
SNP_A-4295370 -0.0493135 0.079 -0.1044368 0.0058099 
SNP_A-1969214 -0.0529695 0.059 -0.1079729 0.002034 
SNP_A-2086003 0.076422 0.018 0.0133527 0.1394913 
SNP_A-2186482 0.133517 0.000 0.0737778 0.1932561 
 
Table 3.8: Linear regression results assuming full dominance of the minor allele using left 
ventricular mass (LVM) as the dependent variable. The p-values are adjusted for the 
covariates age, sex, mean blood pressure over 24 hours (systolic), waist circumference, 
body mass index, diabetes status and the appearance of cardiac heart disease per patient. 
Significant p-values are highlighted red. 
 
As far as the recessive model is concerned, three SNPs with a significant impact on 
left ventricular mass before multivariate correction were significant after correction 
as well (SNP_A-2153126, SNP_A-1935686 and SNP_A-1969214). Regression 
coefficients were almost identical before and after correction. Three markers were 
no longer significant after multivariate adjustment, SNP_A-2065547, SNP_A-
4265373 and SNP_A-4295370. All results for the 10 considered SNPs are displayed 
in Table 3.9. 
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probe set ID regression coefficient p-value 95 % CI 
SNP_A-2153126 0.1681114 0.001 0.0682313 0.2679916 
SNP_A-2065547 0.0122498 0.825 -0.0962807 0.1207803 
SNP_A-1935686 -0.1534794 0.007 -0.2655091 -0.0414497 
SNP_A-4265373 0.1471912 0.06 -0.0063885 0.3007708 
SNP_A-2291035 0.1320233 0.127 -0.0377941 0.3018407 
SNP_A-2140243 -0.0309645 0.709 -0.1939044 0.1319753 
SNP_A-4295370 -0.0728403 0.072 -0.152099 0.0064184 
SNP_A-1969214 -0.1551457 0.008 -0.2689728 -0.0413186 
SNP_A-2086003 0.0614297 0.445 -0.0964647 0.2193241 
SNP_A-2186482 0.5401594 0.078 -0.0600712 1.14039 
 
Table 3.9: Linear regression results assuming full recessiveness of the minor allele using left 
ventricular mass (LVM) as the dependent variable. The p-values are adjusted for adjusted 
for the covariates age, sex, mean blood pressure over 24 hours (systolic), waist 
circumference, body mass index, diabetes status and the appearance of cardiac heart 
disease per patient. Significant p-values are highlighted red. 
 
Overall, there were seven SNPs having a significant effect on LVM after multivariate 
correction, both regarding the dominant model and the recessive model. These 
SNPs were prime candidate SNPs for an obligatory replication concerned in chapter 
3.1.2.4. In Table 3.10, the annotations for the seven probe set IDs are given 
(annotated using NetAffx™). All of the polymorphisms are located in intronic 
regions or upstream respectively downstream of the concerned genes. No SNPs 
located in gene exons were affected. Two SNPs, SNP_A-1935686 and SNP_A-
1969214 are located in the same gene NOS1AP. 
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probe set ID dbSNP rs ID gene relationship gene symbol Entrez gene ID 
SNP_A-1935686 rs10800465 intron NOS1AP 9722 
SNP_A-1969214 rs10919200 intron NOS1AP 9722 
SNP_A-2086003 rs1469943 downstream / upstream PELI1 57162 
SNP_A-2153126 rs629187 intron ALCAM 214 
SNP_A-2291035 rs11564177 intron LRRK2 120892 
SNP_A-4265373 rs1838467 upstream GABRB2 / GABRA6 2561 / 2559 
SNP_A-2186482 rs1475750 upstream / downstream GPR63 81491 
 
Table 3.10: The annotated probe set IDs of the LVH associated and LVM controlling SNPs. 
The corresponding dbSNP (SNP database) rs-number, gene relationship, associated official 
gene symbol and Entrez gene ID (database of the National Center for Biotechnology 
Information (NCBI)) are given. 
 
 
3.1.2.4. Replication of genome-wide candidate SNPs 
Seven SNPs were selected to be valid candidates for a replication approach in 
further affected case samples and unaffected controls. The group of available 
replication samples was described in Table 2.1. Overall, 2969 replication samples 
including two groups of cases (I and II) and one control group were allocated. The 
case group I consisted of the 855 remaining DNA samples from patients of the 
ESTher group exhibiting the same phenotype characteristics as the screening cases. 
The cases II group (n = 470) were recruited independently, all showing an arterial 
hypertension and enlarged left ventricles during echocardiography. Genome-wide 
genotyped (Affymetrix® Genome-Wide Human SNP Array 5.0) KORA control 
samples (n = 1644) served as replication controls. SNP replication in cases I (n = 855) 
and cases II (n = 375) was performed using TaqMan® technology. After genotype 
calling and data recoding for usage in PLINK, association p-values were calculated 
using basic allelic association and logistic regression (dominant and recessive model 
corrected for age and sex). In a first step, the ESTher replication cases were 
compared to the KORA control samples and subsequently the second, independent 
affected data set cases II was compared to the KORA control samples as well. All of 
the SNPs were checked to be in Hardy-Weinberg equilibrium (p-value > 0.001) in the 
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control samples. Table 3.11 shows the resulting association p-values for the seven 
tested candidate SNPs for the replication in the ESTher subgroup and the KORA 
samples. None of the previously determined associations were replicated; the only 
significant p-value (0.01866) was detected using logistic regression (recessive 
model, SNP_A-2086003). Narrowing down the examined phenotype, the same 
calculations were repeated selecting only LVH affected samples from replication 
case I (n = 459). None of the previously determined associations of the seven SNPs 
could be replicated using this approach either (data not shown). Due to the 
disappointing replication results as far as the loci associations to LVH are concerned, 
determination of the impact on the left ventricular mass was dropped. 
 
   allelic assoc. dom. model rec. model 
probe set ID 
MAF     
(cases) 
MAF 
(controls) 
p-value OR p-value OR p-value OR 
SNP_A-1935686 0.264 0.2654 0.9224 0.993 0.7482 0.9708 0.6784 0.9247 
SNP_A-1969214 0.2636 0.2651 0.9133 0.9924 0.6076 0.955 0.966 1.008 
SNP_A-2086003 0.1221 0.1115 0.2864 1.109 0.7836 1.03 0.01866 2.922 
SNP_A-2153126 0.1634 0.1521 0.3251 1.089 0.5365 1.064 0.1913 1.466 
SNP_A-2186482 0.08082 0.09046 0.2782 0.884 0.2818 0.874 0.509 1.355 
SNP_A-2291035 0.1476 0.1453 0.835 1.019 0.9097 1.012 0.5788 1.205 
SNP_A-4265373 0.1455 0.1487 0.7784 0.975 0.3976 0.9155 0.7871 1.077 
SNP_A-4292544 0.4895 0.507 0.2584 0.9323 0.5912 1.057 0.07462 0.8293 
 
 
Table 3.11: Replication results of the seven significant LVH-associated SNPs between the 
screening cases and controls (basic allelic association and logistic regression results) and 
having a significant impact on LVM. Replication was performed using TaqMan® technology, 
genotyping took place in ESTher replication samples (cases I, n = 855) and KORA controls   
(n = 1644). P-values and odds ratios (OR) were determined using basic allelic association 
(allelic assoc.) and logistic regression using the dominant (dom.) and recessive (rec.) model. 
The minor allele frequencies (MAF) in cases and controls are given. Significant p-values are 
highlighted red. 
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The repeated replication using another group of affected samples was unsuccessful 
as well. None of the detected associations in the screening samples could be 
replicated. The only significant associated SNP (SNP_A-2153126) was formerly 
associated without covariate correction using basic allelic association. 
 
   allelic assoc. dom. model rec. model 
probe set ID 
MAF     
(cases) 
MAF 
(controls) 
p-value OR p-value OR p-value OR 
SNP_A-1935686 0.241 0.2654 0.177 0.879 0.2365 0.8672 0.7831 0.933 
SNP_A-1969214 0.2417 0.2651 0.1954 0.8835 0.2519 0.8708 0.8676 0.9587 
SNP_A-2086003 0.1042 0.1115 0.5685 0.9264 0.6572 0.9362 0.4476 1.688 
SNP_A-2153126 0.1732 0.1521 0.1591 1.168 0.6719 1.057 0.02281 2.069 
SNP_A-2186482 0.07597 0.09046 0.2124 0.8266 0.2695 0.8321 0.6012 0.6666 
SNP_A-2291035 0.1507 0.1453 0.7098 1.044 0.9298 1.012 0.5461 1.294 
SNP_A-4265373 0.1527 0.1487 0.7893 1.031 0.8872 0.981 0.1048 1.731 
SNP_A-4292544 0.5083 0.493 0.4562 1.063 0.1936 1.198 0.9311 1.012 
 
 
Table 3.12: Replication results of the seven SNPs that were significantly associated with LVH 
(basic allelic association and logistic regression results) and LVM (linear regression). 
Replication was performed using TaqMan® technology, genotyping took place in cases II    
(n = 375) and KORA controls (n = 1644). P-values and odds ratios (OR) were determined 
using basic allelic association (allelic assoc.) and logistic regression using the dominant 
(dom.) and recessive (rec.) model. The minor allele frequencies (MAF) in cases and controls 
are given. Significant p-values are highlighted red. 
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3.2. Comparative mapping approach 
 
The background for the comparative mapping approach to dissect the genetic basis 
of left ventricular hypertrophy (LVH) as a hypertensive end organ damage was the 
QTL mapping approach performed in the group of Prof. Dr. med. Reinhold Kreutz. 
The linkage analysis was performed using the spontaneously hypertensive rat, 
stroke prone (SHRSP) because the inbred strain exhibits a significant LVH under high 
blood pressure conditions. 
 
3.2.1. QTL mapping 
 
The SHRSP and the contrasting normotensive F344 rats exhibiting normal heart 
weights were crossed and the parental animals (each with n = 6) and the resulting 
F2-animals (n =232) were phenotyped at the age of 14 weeks (see Table 3.13). Only 
male rats were selected to avoid sex bias. Mean systolic blood pressure of the       
F2
 
-animals was 186.85 ± 26.14 mmHg and lay in between the mean systolic blood 
pressure of the parental rats (with mean values of 132 and 262 mmHg respectively). 
The relative left ventricular weight of the intercross animals was slightly increased 
in contrast to the F344 parental animals but far lower than the relative left 
ventricular weight of the SHRSP parental rats. Over all, the systolic blood pressure 
values and the relative left ventricular weight (data not shown) followed a normal 
distribution.  
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 F344 SHRSP F2 SHRSP x F344 
 mean mean min max mean 
systolic blood pressure [mmHg] 132 ± 8 262 ± 23 139 284 186.85 ± 26.14 
rel. left ventricular weight [mg/g] 2.23 ± 0.55 4.27 ± 0.55 2.09 3.88 2.63 ± 0.31 
 
Table 3.13: Phenotype characteristics of F344, SHRSP (each with n = 6) and F2
 
-intercross 
rats (n = 232). The systolic blood pressure (in mmHg) and the relative left ventricular weight 
(in mg left ventricular weight per g body weight) are given. The data were provided by the 
group of Prof. R. Kreutz, Charité Universitätsmedizin Berlin. 
Using the described total genome scan approach and parametric linkage analysis, a 
major quantitative trait locus (QTL) for the relative weight of the left ventricle in the 
232 male F2
 
-animals (SHRSP x F344) was identified. No further significant QTL 
regions were detected on the remaining chromosomes.  
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Figure 3.4: LOD (Log of the Odds) plot for rat chromosome 1 of the complete genome scan 
of 232 male F2-animals from an intercross between SHRSP and F344 rats. The microsatellite 
marker intervals are given in centiMorgan (cM). The blue colored line represents the 
linkage results for the systolic blood pressure. The relative heart weight is plotted in light 
blue (peak LOD 10.51), relative weight of the left ventricle in red (peak LOD 8.38). The 
dotted (LOD 2.8) and solid (LOD 4.3) line mark the significance thresholds for suggestive 
and significant linkage. The figure was provided by the group of Prof. R. Kreutz, Charité 
Universitätsmedizin Berlin. 
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Figure 3.4 shows the resulting LOD plots of the QTL mapping approach for the       
F2-intercross animals between the normotensive F344 rats and the hypertensive 
SHRSP rats on rat chromosome 1. The LOD plots for the three examined phenotypes 
relative heart weight (light blue), relative left ventricular weight (red) and systolic 
blood pressures (blue) are shown. Both, the relative heart weight and relative left 
ventricular weight QTL were significant with LOD scores exceeding the LOD 4.3 
threshold. They showed a parallel curve progression and the peak LODs are 10.51 
and 8.38 respectively. For systolic blood pressure, no significant or suggestive QTL 
was detected providing evidence that the relative left ventricular weight QTL was 
genetic independent from blood pressure in the F2
The phenotype of interest for the comparative mapping approach was the relative 
weight of the left ventricle in the context of hypertension. The corresponding LOD 
plot of the significant QTL peaked at LOD 8.38 and the peak region is flanked by the 
microsatellite markers D1Rat287 and D1Rat159. The 1-LOD decrease region from 
the peak was equal to the region between D1Rat287 and D1Rat159, giving the 
empiric 95 % confidence interval of the relative left ventricular weight QTL.  
- animals.  
 
3.2.2. Comparative mapping of the QTL region 
 
The resulting 95% confidence interval of the relative left ventricular weight QTL 
detected in chapter 3.2.1 ranged from D1Rat287 to D1Rat159. The genomic 
position on rat chromosome 1 for this interval is 190,114,247 - 198,792,612 
resulting in an 8,678,365 base pair (bp) region of interest. 52 annotated putative 
candidate genes (rat genome database) linked to the examined phenotype were 
localized within this interval using BioMart data management system and the rat 
data set rat genome assembly 3.4. In addition, 87 potential transcripts were 
detected within the interval. 
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Using the Rat Genome Browser available on the Rat Genome Database, the 
resulting QTL interval was mapped to the human genome (assembly hg18). The best 
rat/human chain to the mapped rat interval was on the human chromosome 11, 
from genomic position 58,029,502 to 88,990,550 (Δ 30,961,048 bp). Within this 
mapped region, 442 annotated genes (Entrez data base) and 1195 detected 
transcripts were located using BioMart data management system and the GRCh 37 
assembly. Dissecting the resulting comparative mapping region, the corresponding 
HapMap genotype data for Caucasian trios was downloaded from the HapMap 
Project. The genotyped data was uploaded in HaploView to display the linkage 
disequilibrium (LD) pattern of the region (Figure 3.5). Figure 3.5 reveals the LD 
pattern of the comparative mapping region on human chromosome 11. Apparently, 
the region is divided into three separate LD blocks whereas the two flanking blocks 
presumptive range over the interval boundaries.  
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Figure 3.5: Linkage disequilibrium (LD) structure of the human comparative mapping 
region. The 95% confidence interval of the detected relative left ventricular mass QTL      
(F2-intercross of SHRSP x F344 rats) on rat chromosome 1 was mapped on the human 
genome. HapMap genotype data (Caucasian trios) for the resulting comparative mapping 
region on human chromosome 11 was downloaded and the LD pattern was displayed using 
HaploView.  
 
 
Subsequently, the resulting genomic localization was aligned with the result of the 
genome-wide association analysis of left ventricular hypertrophy (LVH) described in 
chapter 3.1. The basis for this alignment were the detected association results of 
the case control approach using the extremes, LVH affected cases from the ESTher 
cohort and the PopGen control samples. The genomic positions of significant 
disease-associated markers of the basic allelic association and logistic regression 
approach were compared with the genomic position of the rat QTL mapped region 
on human chromosome 11 (see chapter 3.1.2.1 and 3.1.2.2). Two significantly 
associated SNPs (logistic model, dominant model, corrected for age and sex, see 
Table 3.4) were detected in the interval region, both located within the intron 1 and 
7 of the gene PACS1 (phosphofurin acidic cluster sorting protein 1, gene ID 55690) 
on chromosome 11q13.1. PACS1 includes 24 exons and a transcript length of 4488 
Results 
 
59 
 
bp. The exact genomic position of the two SNPs is displayed in Table 3.14. PACS1, a 
cytosolic sorting protein is located at the center of the LD block displayed in Figure 
3.5.  
 
probe set ID db SNP ID chromosome bp Gene symbol lokalization 
SNP_A-2064936 rs512421 11 65741744 PACS1 Intron 7 
SNP_A-2079405 rs580891 11 65711257 PACS1 Intron 1 
 
Table 3.14: Genomic position in base pairs (bp) and annotation data of the two significant 
associated SNPs resulting from the genome-wide scan of LVH-affected cases and healthy 
controls corrected for age and sex using logistic regression, dominant model and being 
located within the comparative mapping interval of the rat relative left ventricle weight QTL 
95% confidence interval.  
 
 
3.2.3. Replication of SNPs identified by comparative mapping 
 
The two SNPs described in chapter 3.2.2 were selected for further replication using 
TaqMan® technology. For replication, the previously defined replication samples 
composed of cases group I and II and control samples were used. Replication case 
group I consisted of 855 remaining DNA samples from patients of the ESTher group. 
The cases II group was recruited independently, all showing an arterial hypertension 
and enlarged left ventricles during echocardiography. 375 samples were selected 
for replication out of 470 existing. Genome-wide genotyped (Affymetrix® Genome-
Wide Human SNP Array 5.0) KORA control samples served as replication controls. 
Detailed phenotype data of the replication samples are given in Table 2.1.  
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   allelic assoc. dom. model rec. model 
probe set ID 
MAF 
(cases) 
MAF 
(controls) 
p-value OR p-value OR p-value OR 
SNP_A-2064936 0.2517 0.2333 0.1708 1.106 0.6744 1.04 0.0941 1.674 
SNP_A-2079405 0.2159 0.1765 0.001371 1.285 0.009534 1.28 0.3351 1.234 
 
Table 3.15: Replication results of the two SNPs resulting from the comparative mapping 
approach for the remaining ESTher samples (n = 855) acting as cases and KORA controls (n = 
1644). The minor allele frequencies (MAF) are given for cases and controls. Association with 
LVH was determined using basic allelic association (allelic assoc.) and logistic regression 
with adjustment for age and sex using the dominant (dom.) and recessive (rec.) model. 
Significant p-values are highlighted red. 
 
First, the two SNPs were genotyped in the cases group I and the control samples 
(see Table 3.15). After Hardy-Weinberg quality checking (Hardy-Weinberg p-value ≥ 
0.001 in controls for both SNPs) basic allelic association was determined for the two 
SNPs. SNP_A-2079405 was significantly associated with the examined phenotype 
LVH (p-value 0.001371) having an odds ratio (OR) of 1.285. For SNP_A-2064936, no 
significant association was determined. Subsequently, the calculation was repeated 
correcting the model for age and sex of the samples using logistic regression. Once 
again, the association of SNP_A-2079405 detected in the genome-wide scan was 
replicated (p-value 0.009534). Carriers of minor allele of this SNP have a 1.28-fold 
elevated risk developing of LVH under high blood pressure conditions. The 
combined p-value of the two logistic regression results, for screening and 
replication samples for this SNP was 1.161 * 10-5
 
. 
The replication approach was repeated using the cases group II consisting of 375 
samples (see Table 3.16). The allele frequencies of the two SNPs were checked to be 
in Hardy-Weinberg equilibrium (p-value ≥ 0.001). Once again, the association results 
of the genome-wide scan for SNP_A-2079405 were replicated both, for a basic 
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allelic association p-value of 0.007924 and a p-value after logistic regression of 
0.01832. The combined p-value (see 2.2.4.6) for genome-wide and replication 
association after logistic regression, dominant model is 2.149 * 10-5. In addition, 
logistic regression using the recessive model resulted in a significant p-value for 
SNP_A-2064936 (p-value 3 * 10-4
 
). 
   allelic assoc. dom. model rec. model 
probe set ID 
MAF 
(cases) 
MAF 
(controls) 
p-value OR p-value OR p-value OR 
SNP_A-2064936 0.27 0.2333 0.05661 1.216 0.892 1.018 0.00003 2.578 
SNP_A-2079405 0.2213 0.1765 0.007924 1.327 0.01832 1.364 0.09377 1.61 
 
Table 3.16: Replication results of the two SNPs resulting from the comparative mapping 
approach for the cases group II (n = 375) and KORA controls (n = 1644). The minor allele 
frequencies (MAF) are given for cases and controls. Phenotype associations were 
determined using basic allelic association (allelic assoc.) and logistic regression for age and 
sex correction using the dominant (dom.) and recessive (rec.) model. Significant p-values 
are highlighted red. 
 
Overall, the PACS1-intronic marker SNP_A-2079405 on human chromosome 11 
detected by a genome-wide association study and located within the comparative 
mapped interval of the rat QTL was the first valid association with significant results 
in the two independent replication approaches. Using linear regression (data not 
shown), the impact of the two SNPs on the quantitative trait left ventricular mass 
was tested. Both, neither SNP_A-2079405 nor SNP_A-2064936 showed a significant 
result. 
Using KORA samples as control samples for replication, it was possible to evaluate 
whether the detected associations between SNPs and the phenotype left 
ventricular hypertrophy under hypertensive conditions were independent from high 
blood pressure to exclude that the two markers were associated with the 
phenotype hypertension, and thus only indirectly associated with LVH. A new 
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control sample group was generated, using 770 out of 1644 KORA control samples 
showing a significant arterial hypertension. Basic allelic association and logistic 
regression using the dominant model was repeated with both replication cases 
groups as described above. The resulting p-values and OR are shown in Table 3.17 
and Table 3.18. 
 
 repl. cases I vs. KORA (all, n = 1644) 
 allelic assoc. dom. model rec. model 
probe set ID p-value OR p-value OR p-value OR 
SNP_A-2064936 0.1708 1.106 0.6744 1.04 0.0941 1.373 
SNP_A-2079405 0.00137 1.285 0.009534 1.28 0.3351 1.234 
 repl. cases I vs. KORA (a. hypert., n = 770) 
SNP_A-2064936 0.09703 1.153 0.4522 1.089 0.1791 1.388 
SNP_A-2079405 0.00347 1.311 0.01174 1.346 0.9276 1.024 
 
Table 3.17: Repeated replication analysis using n = 770 arterial hypertension (a. hypert.) 
affected controls versus (vs.) replication (repl.) cases group I (n = 855). Basic allelic 
association (allelic assoc.) determination and logistic regression, dominant and recessive 
model (dom. and rec., corrected for age and sex) was repeated. Significant p-values are 
highlighted red. 
 
 repl. cases II vs. KORA (all, n = 1644) 
 allelic assoc. dom. model rec. model 
probe set ID p-value OR p-value OR p-value OR 
SNP_A-2064936 0.05661 1.216 0.892 1.018 0.00003 2.578 
SNP_A-2079405 0.007924 1.327 0.01832 1.364 0.09377 1.61 
 repl. cases II vs. KORA (a. hypert., n = 770) 
SNP_A-2064936 0.03367 1.268 0.6823 1.06 0.00012 2.677 
SNP_A-2079405 0.009983 1.353 0.0161 1.406 0.2882 1.386 
 
Table 3.18: Repeated replication analysis using n = 770 arterial hypertension (a. hypert.) 
affected controls versus (vs.) replication (repl.) cases group II (n = 375). Basic allelic 
association (allelic assoc.) determination and logistic regression, dominant and recessive 
model (dom. and rec., corrected for age and sex) was repeated. Significant p-values are 
highlighted red. 
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The levels of significance remained almost identical except for SNP_A-2079405 
using logistic regression (dominant model, cases I vs. KORA), the p-value increased 
from about 0.009 to 0.01 but remains significant (p-value ≤ 0.05). Using logistic 
regression assuming full recessiveness and basic allelic association the results for 
both SNPs had the same dimension after using arterial hypertension affected 
samples as controls. For replication cases II, the marker SNP_A-2064936 got 
significant when using arterial hypertension affected KORA controls instead of all 
KORA samples (from 0.05661 to 0.03367).  
 
 
3.2.4. Fine mapping of PACS1 region 
 
The two markers (SNP_A-2079405 and SNP_A-2064936) within the introns of PACS1 
were the only valid SNPS associated with left ventricular hypertrophy (LVH). 
Therefore, PACS1 was determined as a new candidate gene for LVH and selected for 
downstream analysis addressing the attributable genetic variance lying within this 
genomic region. As described in chapter 3.2.2, PACS1 is located within a block of 
linkage disequilibrium (LD) on human chromosome 11 as far as HapMap Caucasian 
genotype data is concerned. The LD block ranges from chromosome 11, base pair 
position 65,544,242 to 65,817,122 (~ 273 Mb) with the flanking markers rs3829937 
and rs479018. The corresponding genomic region is displayed in Figure 3.6. Nine 
annotated genes are located within the described LD block (see Figure 3.6). PACS1 is 
located in the middle of the block, it is the largest gene. Downstream of PACS1, 
there are three further genes (CATSPER1, GAL3ST3 and SF3B2) and upstream five 
genes (KLC2, RAB1B, Y1F1A, TEM1 and CNIH2). 
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Figure 3.6: PACS1 is located within a block of strong LD. The genomic structure of this 
region (chromosome 11, base pair position 65,544,242 to 65,817,122) is shown with the 
corresponding annotated genes. 
 
 
Using HaploView, the haplotype composition of the LD block was estimated (see 
Figure 3.7). The HaploView SNP ID is given above each polymorphism. The SNPs are 
not numbered consecutively because all SNPs genotyped in the HapMap Project are 
downloaded for the analysis but only polymorph markers were displayed in 
HaploView. All haplotypes having a frequency above 3% were examined. Nine 
haplotypes were detected with frequencies between 17.4 % and 3.1 %. 
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Figure 3.7: Haplotype structure of the PACS1 containing LD block. For lack of space, the 
block was divided into two sections. All haplotypes having a frequency above 3 % are 
displayed. The numbers above each SNP (n = 263) are HaploView internal IDs. Tagging SNPs 
are labeled by arrows.  
 
 
 
Seven tagging SNPs were determined using HaploView and labeled with arrows 
(Figure 3.7). These seven SNPs (or SNPs having the same information) were selected 
for a further analysis to dissolve the LD block. The seven tagging SNPs are displayed 
in Table 3.19.  In Figure 3.7, the two underlying SNPs SNP_A-2079405 and      
SNP_A-2064936 are numbered with 285 and 320 respectively. 
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dbSNP ID bp gene symbol 
rs947847 65550518 CATSPER1 
rs12576969 65559054 CATSPER1 and GAL3ST3 
rs2452680 65576259 GAL3ST3 and SF3B2 
rs576740 65609147 PACS1 
rs11227408 65625547 PACS1 
rs17494956 65749015 PACS1 
rs556595 65814658 CNIH2 and YIF1A 
 
Table 3.19: Selected tagging SNPs to dissolve the PACS1-containing LD block. The base pair 
positions and the proximate genes are given. 
 
Using TaqMan® technology, the seven SNPs were genotyped to resolve the LD 
structure of the PACS1 containing block on chromosome 11. The replication 
samples cases I (n = 855) and cases II (n = 470) were used. To avoid possible 
technology bias comparing genotypes resulting from TaqMan® technology and 
Affymetrix® SNP Array, 736 KORA samples out of the 1644 available samples served 
as control samples and were genotyped using TaqMan® technology as well. 
Unfortunately, genotyping of one out of seven SNPs failed (rs17494956) and the 
marker was excluded from analysis. 
Basic allelic association and logistic regression assuming full dominance or 
recessiveness (correction for age and sex) was determined for both groups of 
affected samples in contrast to the KORA control samples, the resulting p-values 
and OR are shown in Table 3.20. Once again, the association analysis was repeated 
using only hypertensive control samples (n = 372). The allele frequencies of the 
remaining six SNPs were checked to be in Hardy-Weinberg equilibrium (p-value ≥ 
0.001). All minor allele frequencies (data not shown) were greater than 5 %. 
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  repl. cases I vs. KORA (all, n = 736) repl. cases II vs. KORA (all, n = 736) 
  allelic assoc. dom. model rec. model allelic assoc. dom. model rec. model 
gene symbol dbSNP ID p-value OR p-value OR p-value OR p-value OR p-value OR p-value OR 
CATSPER1 rs947847 0.2656 1.095 0.1377 1.184 0.4034 1.185 0.8997 1.012 0.8077 1.031 0.5309 0.8645 
CATSPER1 and GAL3ST3 rs12576969 0.1228 1.161 0.3437 1.123 0.8779 1.9492 0.6642 1.052 0.3729 1.126 0.4132 0.7056 
GAL3ST3 and SF3B2 rs2452680 0.1558 1.128 0.07633 1.225 0.3706 1.23 0.9388 0.9922 0.8305 1.027 0.1222 0.6396 
PACS1 rs576740 0.00109 1.269 0.2344 1.153 0.0010 1.59 0.02383 1.215 0.0557 1.287 0.05712 1.346 
PACS1 rs11227408 0.1818 0.8163 0.1911 0.793 0.8296 0.8589 0.1314 0.7585 0.1987 0.7803 0.9985 1.052 
CNIH2 and YIF1A rs556595 0.4062 0.938 0.5537 0.9232 0.8319 0.9706 0.182 0.8821 0.1001 0.787 0.9881 0.9977 
  repl. cases I vs. KORA (a. hypert., n = 372) repl. cases II vs. KORA (a. hypert., n = 372) 
CATSPER1 rs947847 0.2085 1.136 0.04735 1.322 0.5573 1.156 0.6707 1.05 0.4522 1.115 0.41 0.8048 
CATSPER1 and GAL3ST3 rs12576969 0.7194 1.043 0.9535 0.9913 0.3694 0.707 0.6657 0.9442 0.9187 1.016 0.1726 0.5367 
GAL3ST3 and SF3B2 rs2452680 0.1248 1.177 0.02701 1.369 0.5996 1.157 0.7752 1.035 0.4827 1.108 0.1083 0.5965 
PACS1 rs576740 0.0050 1.288 0.0797 1.292 0.0134 1.546 0.03841 1.233 0.04564 1.354 0.1955 1.266 
PACS1 rs11227408 0.7695 0.9453 0.4807 0.8558 0.3796 2.809 0.5506 0.8779 0.5825 0.8825 0.9993 0.412 
CNIH2 and YIF1A rs556595 0.4846 0.9375 0.7351 0.9461 0.6512 0.9265 0.2409 0.8817 0.1338 0.7785 0.9503 0.989 
 
Table 3.20: Replication results of the six tagging SNPs to dissolve the PACS1-containing LD block. Replication was performed using TaqMan® 
technology, 855 cases I, 470 cases II and 736 KORA controls were genotyped. Phenotype associations were determined using basic allelic association 
(allelic assoc.) and logistic regression for age and sex correction using the dominant (dom.) and recessive (rec.) model. Association analysis was 
repeated using hypertensive KORA controls (a. hypert., n = 372) as control samples. Significant p-values are highlighted red. 
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The replication results of the six remaining tagging SNPs are shown in Table 3.20. 
Two SNPs (rs947847 and rs2452680) were significant (p-value ≤ 0.05) associated 
with the LVH phenotype after correction for age and sex using the dominant model. 
One SNP, rs576740 located within intron 1 of PACS1 (like SNP_A-2079405, see 
chapter 3.2.3) was associated significantly using basic allelic association showing a 
p-value of 0.001 for cases I and 0.023 for cases II respectively.  Minor allele carriers 
of this SNP have a 1.215-fold to 1.28-fold elevated risk developing of LVH under 
high blood pressure conditions. This effect corresponds with the previous findings 
for the effect of SNP_A-2079405. The repeated calculations using hypertensive 
KORA controls confirms these findings, the p-values and OR were of the same 
magnitude as previously reported giving evidence that the detected association is 
independent of high blood pressure as well. After correction for age and sex, 
rs576740 became significant using the recessive model in cases group I in 
comparison to both KORA control groups. No significant associations were 
determined assuming full dominance except for a slight amendment in cases II 
compared to hypertension affected control samples resulting in a significant p-value 
of 0.045. For the remaining tagging SNPs, no significant phenotype association was 
detected. 
 
Subsequently, genotyping results of the six tagging SNPs were used to reveal LD 
structure and haplotype association using HaploView. The patterns of LD and 
haplotype occurrence were determined for both, comparison of cases I (n = 855) 
and cases II (n = 470) versus all KORA (n = 736) controls and the hypertensive KORA 
controls (n = 372). The resulting LD pattern and haplotype frequencies are 
comparable and thus only displayed using all KORA controls (Figure 3.8 and Figure 
3.9). 
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Figure 3.8: LD structure and haplotype frequencies of the PACS1 region using genotype 
data of six tagging SNPs (see Table 3.19) following from replication in cases I and KORA 
controls. Haplotype blocks were selected manually (a). Five out of six genotyped SNPs are in 
LD, the frequencies for the resulting eight haplotypes are given (b). 
 
In Figure 3.8, the resulting LD structure of the six genotyped tagging SNPs in cases I 
and KORA control samples is displayed. One LD block could be detected, ranging 
from rs947847 to rs11227408 (a). The frequencies of the resulting haplotypes are 
given in Figure 3.8 b. The most prominent haplotype AGAAA occurs in 43.8 %. The 
second common haplotype GGGGA (19.2 %) is the only significantly LVH associated 
haplotype (p-value 0.0281, χ2
In a uniform manner, LD and haplotype analysis was performed using genotype data 
of cases II and the KORA control samples (Figure 3.9). The detected LD block ranges 
from rs947847 to rs11227408 as well and the resulting haplotype frequencies are 
comparable. Two haplotypes are associated significantly in this approach, AGAGA 
occurring with 6.4 % (p-value 0.0475, χ
 4.82). 
2 3.928) and GGAGA with 2.7 % (p-value 
0.047, χ2
 
 3.947). 
a b 
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Figure 3.9: LD structure and haplotype frequencies of the PACS1 region using genotype 
data of six tagging SNPs (see Table 3.19) following from replication in cases II and KORA 
controls. Haplotype blocks were selected manually (a). Five out of six genotyped SNPs are in 
LD, the frequencies for the resulting eight haplotypes are given (b). 
 
Unfortunately, the LD structure of the candidate gene region of PACS1 could not be 
completely resolved in our two studies due to a missing tagging SNP. However, 
significant haplotype-phenotype associations were detected. 
In the future additional block dissolving tagging SNPs should be genotyped. Another 
possible way resolving the genetic variance underlying the PACS1 region would be 
targeted resequencing. Further studies involving animal models e.g. zebrafish or 
knock-out rats will be required to confirm or refute PACS1 as the underlying 
causative gene. 
 
a b 
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4. Discussion 
 
The importance to dissect the genetic background of left ventricular hypertrophy 
(LVH) under high blood pressure conditions is undisputed due to the high LVH 
prevalence in hypertensives and its role as an independent risk factor for several 
heart diseases. This challenge requires appropriate methods to investigate the 
underlying genetic basis. Therefore a genome-wide association study (GWAS) 
approach was chosen to dissect the global mechanisms of developing LVH. The 
resulting genotype-phenotype association data was combined with linkage data 
from a rat model using a comparative mapping approach to provide a proof-of-
concept for the analysis of complex traits. In the following section, the chosen 
GWAS design, its implementation and the resulting associated genetic variants are 
discussed. Finally, the prospects of comparative mapping approaches for the 
interpretation of GWAS are addressed and an outlook on future developments in 
the dissection of the genomic architecture underlying hypertensive LVH is given. 
 
 
4.1. The genome-wide association study design 
 
The potential of GWAS to uncover modest genetic risk factors in complex disease 
has been confirmed in a multitude of robustly identified disease associated loci. 
GWAS is the current method of choice to dissect non-Mendelian multifactorial traits 
(Johnsons AD and O´Donell CJ 2009). In this thesis a case control study design was 
chosen for genome-wide analysis of LVH predisposing genetic variants. The case 
control methodology is straight forward in comparison to other options such as 
family-based methods e.g. parent-affected-child-trios or cohort study designs. The 
main advantage is a rapid recruitment of large numbers of affected individuals 
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through clinical centers and, from a statistical perspective, the best option 
concerning numbers of individuals needed to achieve sufficient statistical power to 
detect a moderate effect through association studies. Therefore the approach is 
relatively cost-effective. On the other hand, the case control design carries the most 
assumptions. Ascertainment within the same population is implied to avoid 
population stratification and differences in allele frequencies are supposed to be 
related to the examined phenotype instead to population differences. Another basic 
presumption in this study design are well phenotyped and representative case and 
control samples (Pearson TA 2008).  
In our study screening and replication samples for the group of cases and controls 
were all recruited in Germany and samples selected for genotyping are of Caucasian 
descent. Consequently, the sample selection for GWAS meets the basic 
requirements to avoid population stratification, as reflected in the moderate 
genomic inflation factor and comparable allele frequencies in the two independent 
study samples investigated. Fortunately, arterial hypertension and LVH are 
phenotypes which can be diagnosed through non-invasive and standardized 
methodologies i.e. echocardiography, rendering misclassification of screening and 
replication cases unlikely. In addition the ESTher survey provided us with plenty 
available phenotype data for multivariate analysis and to include possible 
environmental interactions in the genetic analysis. Control samples utilized for 
screening and replication are usually less well phenotyped and consequently, it is 
questionable whether control samples are really disease free. The controls from the 
PopGen program used in the screening step were normotensive, but on average 
younger than the screening cases; thus age-dependent development of 
hypertension is possible and could introduce bias into the analysis. The use of 
hypertensive control samples with clear normal left ventricular mass checked by 
echocardiography would be more sophisticated, but cost-intensive. Control samples 
used for the replication were ascertained through the KORA survey and consist of 
both, normotensive and hypertensive samples, unfortunately without left 
ventricular mass. Due to a high prevalence of LVH in hypertensive individuals, 
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affected samples in this control subgroup could not be excluded and a 
misclassification of cases versus controls might reduce the statistical power of our 
analysis. Nevertheless, these controls enabled a reduction of misclassified 
individuals since the KORA controls are currently the best phenotyped population 
controls available for such analyses. 
An established strategy for implementing a GWAS is using a multistage approach to 
minimize sample size and the amount of required genotyping, primarily the cost-
intensive genome-wide scan. Genome-wide interrogation is typically performed in a 
small fraction of samples in the first step followed by replication steps of the 
identified associated single nucleotide polymorphisms (SNPs) in larger sample sizes 
to increase statistical power and to ensure findings for variants with modest effects 
in complex traits (Hirschhorn JN and Daly MJ 2005). This multistage design was 
adapted in our study using a relatively small number of screening samples to scan 
the entire genome for disease associated variants. Subsequently, the identified 
SNPs were retested in larger sample size and different population, respectively. For 
high throughput genotyping in stage one, the Affymetrix® Genome-Wide Human 
SNP Array 5.0 was chosen. At that time, the SNP chip was the best choice having a 
genomic coverage of 64 % in the CEU HapMap samples and a number of 575 
uncovered genes. In the meantime, more comprehensive SNP chip types are 
available covering for example 93 % of the SNP content of the CEU HapMap samples 
and only eight genes without SNP coverage like the Illumina Human1M (Li M 2008). 
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4.2. How to find associations in screening samples 
 
 A typical age-related disease like LVH as a hypertensive end-organ damage is a very 
heterogeneous phenotype due to a multitude of secondary disorders like obesity or 
type 2 diabetes and therefore hard to analyze. Moreover, LVH is defined as an 
increase in left ventricular mass in relation to body height and is therefore a 
quantitative phenotype. A strict exclusion of hypertensive patients with increased 
left ventricular masses not affected with LVH by definition may lead to a lack of 
information. In addition, the used screening control samples might be not disease 
free due to the described lack of phenotype data. Having these limitations in mind, 
a case control approach was chosen genotyping the extreme cases of the screening 
samples under stringent conditions. The minor allele frequency threshold was e.g. 
defined to 10 % to avoid miscalled polymorphisms due to the small number of 
genotyped samples. As our genome-wide scan revealed no significant associations 
exceeding the threshold of adjusted p<10-6 as reported in GWAS for other disease 
traits, a threshold of unadjusted association p-value of 0.00001 was chosen to 
obtain a reasonable number of SNPs. Furthermore adjustment for age and sex was 
crucial due to phenotype differences in comparison to the control samples as 
mentioned in 4.1. Subsequently the resulting list of significantly associated SNPs 
was compared with the results of previously described genetic analysis of LVH 
introduced in chapter 1.4. Conducting the HyperGen Study population - a family-
based study for hypertensives – suggestive linkage was observed on chromosome 2, 
4 and 21 for left ventricular mass in whites. None of our significant SNPs were 
located within these genomic regions (Arnett DK 2009; Tang W 2009). In a pilot case 
control GWAS, the HyperGen Study identified three SNPs on chromosome 5 and 12 
robustly associated with increased left ventricular mass in Whites (Arnett DK 2009). 
These associations could not be confirmed in our study. Furthermore a gene 
expression study was published combining linkage and expression analysis of LVH 
affected rats and humans. A list of differentially expressed putative candidate genes 
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in humans associated with left ventricular mass is available (Petretto E 2008). None 
of our significant SNPs is located in one of them or other previously described 
candidate genes.  
As there was no association with known polymorphisms or candidate genes in our 
analysis we focused downstream analyses on those SNPs, which were on the top of 
our list of associated SNPs ordered by stringency. A basic premise of our analysis 
was that variants associated significantly with LVH under high blood pressure 
conditions should have an impact on the size of the left ventricle. For this reason 
subsequent steps involved linear regression analyses of quantitative traits affecting 
LVH on top of simple case control association. Finally SNPs exhibiting significant 
associations with the LVH phenotype and having an impact on the left ventricular 
mass were selected as putative candidate SNPs for replication. In this context one of 
the most interest candidate genes was NOS1AP. Our GWAS analysis exhibited two 
significantly associated SNPs within NOS1AP. In the recent past four different 
variants nearby and within this gene were shown to be associated with sudden 
cardiac death and cardiac repolarization respectively (Eijgelsheim M 2009; Nolte IM 
2009). 
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4.3. Replication – a demanding task 
 
Techniques like correction for multiple testing are insufficient to separate the entire 
plethora of false-positive associations from the few true associations with disease in 
GWAS. An essential step in GWAS is replication of association in a larger number of 
cases and controls or in independent samples. As outlined in the previous sections 
of this thesis, several case and control samples for the required replication 
approach were available. For replication purposes, two groups of case samples 
were analyzed, extension cases of the screening group and independent case 
samples of another survey each with a sufficient number of individuals. Control 
samples utilized for replication were different from the screening samples having a 
gain of information due to a known hypertension status. 
Unfortunately replication of genotype-phenotype associations often fails. A lack of 
reproducibility of associations is a well-known fact, which has already hampered the 
interpretation of candidate-gene approaches in recent years. This drawback is even 
greater in GWAS due to the very large numbers of SNPs simultaneously tested. Thus 
it is an even greater challenge to separate true associations from the blizzard of 
false positives. In general, a lot of reasons can be specified for a missed replication 
of association. Commonly discussed problems are e.g. small samples sizes yielding 
in low power to detect variants of minor to moderate effects. Phenotype 
differences and heterogeneity in classification of outcomes between the screening 
and replications samples are problematic as well, since e.g. selection bias between 
different clinical centers and different methods to assess the disease are likely and 
hard to control. Another pitfall in replication studies might be a poor study design 
resulting in populations stratification or differences in exposure to environmental 
factors (NCI-NHGRI Working Group on Replication in Association Studies 2007).  
In this thesis, the initial seven candidate SNPs determined in the screening samples 
by GWAS were replicated in the described two approaches using extension and 
independent case samples and much to our disappointment none of the initial valid 
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associations was replicated. Even though a lot of basic requirements for a successful 
replication like ascertainment of individuals in the same or similar population were 
met, versatile reasons for this lack of reproducibility are existent and are outlined in 
the following. First of all, the sample size of the replication study, particularly for 
the independent cases, is borderline to ensure sufficient power to detect 
associations at moderate effect sizes. Selection bias between the screening cases 
and the independent replication cases is possible due to sample recruitment in 
different clinical centers. However selection bias cannot be the reason for failed 
replication in the extension cases of the screening group. As mentioned above no 
echocardiography data is available for the control samples used in the replication 
study. Therefore it is questionable whether control samples are really disease free 
and consequently permit to find a genotype-phenotype association. 
Because of the disappointing replication results the reported GWAS design has to 
be challenged. The drawbacks of the applied GWAS discussed in chapter 4.2 might 
be too broad to find associations worth replication. 
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4.4. To learn one´s lesson from comparative genomics 
 
The identification of a robustly replicated SNP-disease association is crucial in 
identifying disease underlying genetic variants. Unfortunately, we were unable to 
replicate any of the initial candidate SNPs. Instead of dropping the GWAS results, 
we decided to implement a comparative genomics approach to dissect the genetic 
basis of LVH under high blood pressure conditions. 
For the comparative mapping approach, a rat disease model for hypertensive left 
ventricular hypertrophy (spontaneously hypertensive rat, stroke prone, SHRSP) was 
chosen. The laboratory rat is the most explored experimental animal model by far 
playing a major role in the study of for example physiology traits. This is due to its 
pioneer role in domesticating mammalian species for scientific research. The 
greatest asset using rat models are a lot of well characterized disease models 
generated by selective breeding. In particular, many inbred models have been 
developed carrying variation leading to common disease phenotypes like 
hypertension or diabetes. A long time the mouse has eclipsed the rat as a genetic 
model (Jacob HJ 1999). In the recent past there has been an increase in rat genomic 
resources including microsatellite markers, linkage maps, gene expression data and 
the rat genome sequence followed by a catalogue of about 3 million SNP markers. 
In addition appropriate database structures for the efficient use of available data 
like the rat genome database (RGD) were developed (Aitman TJ 2008). These 
attributes are reflected by a package of 22 significant quantitative trait loci (QTL) for 
left ventricular mass publically available for different rat strains data mining the 
RGD. For the comparative mapping approach QTL data of a rat strain was chosen 
with similar attributes to our human phenotype of interest. The SHRSP rat develops 
hypertension and a strong LVH phenotype under normal conditions, enhanced by 
an increased salt intake. Furthermore, the examined locus on rat chromosome 1 
shows a remarkable strong linkage to an enlarged left ventricle. The region mapped 
to a significantly larger region on in the human genome on chromosome 11. 
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Interestingly, two significantly associated markers dropped primarily due to a lack of 
impact on left ventricular mass were detected within intron 1 and 7 of the 
phosphofurin acidic cluster sorting protein 1 (PACS1). These SNPs, SNP_A-2064936 
and SNP_A-2079405 were replicated robustly in both, the extension cases of the 
screening group and the independent case samples and, therefore, were taken 
forward to a downstream analysis of the PACS1 region. Each of the minor alleles of 
the two SNPs represents risk alleles for developing LVH. The fine mapping was 
performed to address the attributable genetic variance within this genomic region. 
Further genotyping to resolve the complete underlying genomic region revealed 
another PACS1 intronic SNP (rs576740), which was associated with LVH in 
hypertensives in downstream analyses. For this reason, we believe that PACS1 is a 
serious new candidate gene involved in the development of LVH as hypertensive 
end organ damage.  
Interestingly reasons for a failed replication of LVH-associated SNPs discussed in 
chapter 4.3 were abrogated by confirming the results for PACS1 variants. In all 
probability the initial GWAS approach is not adequate to find valid associations for 
LVH under high blood pressure conditions and needs the benefit of comparative 
genomics to increase power of the findings. Furthermore the question arise as to 
why variants robustly associated with LVH in hypertensives as those of PACS1 do 
not have an impact on the left ventricular mass, a prior criterion for exclusion of the 
study. Maybe, gene-gene interactions are included in the LVH underlying molecular 
mechanisms that are not detected by GWAS. 
To our knowledge, PACS1 was described never before in connection with a genetic 
association study or heart-associated diseases. PACS1 is a coat protein which 
localizes membrane proteins in mammalian cells to the trans-Golgi network (TGN) 
(Wan L 1998). As an intracellular sorting protein, it directs the localization of furin 
and mannose 6-phosphat receptor connecting them to components of the clathrin 
sorting machinery and it is involved in ion channel trafficking to distinct subcellular 
compartments (Köttgen M 2005). Recent findings suggest that PACS1 is involved in 
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the control of ciliary localization of several ion channels and other membrane 
proteins. Cilia are located on the surface of nearly any mammalian cell. They are 
microtubule based organelles lacking own protein synthesis. Therefore proteins 
must be transported into the cilium by several trafficking proteins like PACS1. 
Deregulation of this protein localization results in a multitude of disease 
phenotypes called ciliophaties e.g. retinal degeneration or polycystic kidney disease 
(Jenkins PM 2009). Alteration in cilia function of myocytes due to PACS1 may lead to 
a change in response to increased biomechanical stress under high blood pressure 
conditions closing in hypertrophy. 
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4.5. Outlook 
 
It is in the nature of GWAS to identify a genomic location related to disease but 
provide little information on gene function. Therefore, functional studies will be 
required to dissect the molecular mechanisms of the examined phenotype and the 
putative role of genes with associated SNPs. 
In this thesis, PACS1 was identified as a candidate gene influencing development of 
LVH under high blood pressure conditions due to three significantly associated 
intronic SNPs. Unfortunately, the attributable genetic variance within the PACS1 
gene region could not be completely resolved due to missing tagging SNPs. 
Additional tagging SNPs genotyped in the near future will help to resolve the 
genomic region and to extend the finding of haplotype-phenotype associations. 
Targeted resequencing using next-generation sequencing in a couple of adequate 
samples provides another possibility to resolve the PACS1 region. 
To gain insight into the function of PACS1 in vivo a set of methods using animal 
models is available. An elegant way to quickly functionally assess PACS1 is to 
conduct Morpholino antisense knockdown experiments using the orthologous loci 
pacs1 in zebrafish, where cardiac phenotypes can be readily assessed through direct 
monitoring of the heart in the living animal (Nasevicius A 2000). Another promising 
approach would be the analysis of PACS1 function in the original dissected model, 
the SHRSP rat. Thus, different strategies are available but will require a significant 
amount of time, exceeding the scope and timeframe of this thesis. Generation of 
consomic and congenic rat strains of the SHRSP rat carrying chromosome 1 or only 
the region linked to an increased left ventricular mass of a healthy rat are under 
way. Data not published yet gives evidence that these rats have decreased left 
ventricular masses. A whole-genome gene expression experiment using Illumina 
technology is in progress assessing the transcription profile of left ventricle tissue of 
normotensive F344 control rats and SHRSP rats and the respective consomic strains. 
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Recently, a gene targeting approach to generate knockout rats was published using 
zinc-finger nucleases (ZFNs) induce site-specific, double-strand DNA breaks. The 
ZFNs-encoding mRNA is delivered to rat embryos via microinjection (Geurts AM 
2009). This innovative approach closes the gap between mouse and rat functional 
genetics and enables a PACS1 knockout in our disease model SHRSP to identify it at 
least as a causative gene or not. For this reason in the end, the wheel of our 
comparative mapping approach comes to full circle. On one hand it is a powerful 
tool to facilitate genome-wide analysis in humans like our GWAS. On the other hand 
comparative genomics provide an opportunity to confirm or to refuse a newly 
detected candidate gene. 
Writing this thesis generated a lot of new ideas to enhance the dissection of the 
genetic basis of LVH in hypertensives. As mentioned above a multitude of 
phenotype data is available for the genome-wide genotyped screening samples. 
Subphenotype analysis is required considering the effect of antihypertensive drugs 
e.g. the drug type or the time period of drug intake. Moreover other approaches to 
find associated polymorphisms like haplotype based methods are possible. 
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